false --06-30 2026 Q2 0000725394 0000725394 2025-07-01 2025-12-31 0000725394 2026-02-20 0000725394 2025-12-31 0000725394 2025-06-30 0000725394 DHTI:SeriesIPreferredStockMember 2025-12-31 0000725394 DHTI:SeriesIPreferredStockMember 2025-06-30 0000725394 us-gaap:SeriesHPreferredStockMember 2025-12-31 0000725394 us-gaap:SeriesHPreferredStockMember 2025-06-30 0000725394 us-gaap:SeriesGPreferredStockMember 2025-12-31 0000725394 us-gaap:SeriesGPreferredStockMember 2025-06-30 0000725394 us-gaap:SeriesFPreferredStockMember 2025-12-31 0000725394 us-gaap:SeriesFPreferredStockMember 2025-06-30 0000725394 DHTI:UnrelatedPartiesMember 2025-10-01 2025-12-31 0000725394 DHTI:UnrelatedPartiesMember 2024-10-01 2024-12-31 0000725394 DHTI:UnrelatedPartiesMember 2025-07-01 2025-12-31 0000725394 DHTI:UnrelatedPartiesMember 2024-07-01 2024-12-31 0000725394 DHTI:RelatedPartiesMember 2025-10-01 2025-12-31 0000725394 DHTI:RelatedPartiesMember 2024-10-01 2024-12-31 0000725394 DHTI:RelatedPartiesMember 2025-07-01 2025-12-31 0000725394 DHTI:RelatedPartiesMember 2024-07-01 2024-12-31 0000725394 2025-10-01 2025-12-31 0000725394 2024-10-01 2024-12-31 0000725394 2024-07-01 2024-12-31 0000725394 DHTI:PreferredStockSeriesIMember 2025-06-30 0000725394 DHTI:PreferredStockSeriesHMember 2025-06-30 0000725394 DHTI:PreferredStockSeriesGMember 2025-06-30 0000725394 DHTI:PreferredStockSeriesFMember 2025-06-30 0000725394 DHTI:PreferredStockSeriesIMember 2025-09-30 0000725394 DHTI:PreferredStockSeriesHMember 2025-09-30 0000725394 DHTI:PreferredStockSeriesGMember 2025-09-30 0000725394 DHTI:PreferredStockSeriesFMember 2025-09-30 0000725394 us-gaap:CommonStockMember 2025-06-30 0000725394 DHTI:CommonStockToBeIssuedMember 2025-06-30 0000725394 DHTI:PreferredStockToBeIssuedMember 2025-06-30 0000725394 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0000725394 us-gaap:CommonStockMember 2025-09-30 0000725394 DHTI:CommonStockToBeIssuedMember 2025-09-30 0000725394 DHTI:PreferredStockToBeIssuedMember 2025-09-30 0000725394 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0000725394 us-gaap:RetainedEarningsMember 2025-06-30 0000725394 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-06-30 0000725394 DHTI:TotalDalradaFinancialCorpsStockholdersDeficitMember 2025-06-30 0000725394 us-gaap:NoncontrollingInterestMember 2025-06-30 0000725394 us-gaap:RetainedEarningsMember 2025-09-30 0000725394 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-09-30 0000725394 DHTI:TotalDalradaFinancialCorpsStockholdersDeficitMember 2025-09-30 0000725394 us-gaap:NoncontrollingInterestMember 2025-09-30 0000725394 2025-09-30 0000725394 DHTI:PreferredStockSeriesIMember 2025-07-01 2025-09-30 0000725394 DHTI:PreferredStockSeriesHMember 2025-07-01 2025-09-30 0000725394 DHTI:PreferredStockSeriesGMember 2025-07-01 2025-09-30 0000725394 DHTI:PreferredStockSeriesFMember 2025-07-01 2025-09-30 0000725394 DHTI:PreferredStockSeriesIMember 2025-10-01 2025-12-31 0000725394 DHTI:PreferredStockSeriesHMember 2025-10-01 2025-12-31 0000725394 DHTI:PreferredStockSeriesGMember 2025-10-01 2025-12-31 0000725394 DHTI:PreferredStockSeriesFMember 2025-10-01 2025-12-31 0000725394 DHTI:PreferredStockSeriesIMember 2025-07-01 2025-12-31 0000725394 DHTI:PreferredStockSeriesHMember 2025-07-01 2025-12-31 0000725394 DHTI:PreferredStockSeriesGMember 2025-07-01 2025-12-31 0000725394 DHTI:PreferredStockSeriesFMember 2025-07-01 2025-12-31 0000725394 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0000725394 DHTI:CommonStockToBeIssuedMember 2025-07-01 2025-09-30 0000725394 DHTI:PreferredStockToBeIssuedMember 2025-07-01 2025-09-30 0000725394 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0000725394 us-gaap:CommonStockMember 2025-10-01 2025-12-31 0000725394 DHTI:CommonStockToBeIssuedMember 2025-10-01 2025-12-31 0000725394 DHTI:PreferredStockToBeIssuedMember 2025-10-01 2025-12-31 0000725394 us-gaap:AdditionalPaidInCapitalMember 2025-10-01 2025-12-31 0000725394 us-gaap:CommonStockMember 2025-07-01 2025-12-31 0000725394 DHTI:CommonStockToBeIssuedMember 2025-07-01 2025-12-31 0000725394 DHTI:PreferredStockToBeIssuedMember 2025-07-01 2025-12-31 0000725394 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-12-31 0000725394 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0000725394 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-07-01 2025-09-30 0000725394 DHTI:TotalDalradaFinancialCorpsStockholdersDeficitMember 2025-07-01 2025-09-30 0000725394 us-gaap:NoncontrollingInterestMember 2025-07-01 2025-09-30 0000725394 2025-07-01 2025-09-30 0000725394 us-gaap:RetainedEarningsMember 2025-10-01 2025-12-31 0000725394 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-10-01 2025-12-31 0000725394 DHTI:TotalDalradaFinancialCorpsStockholdersDeficitMember 2025-10-01 2025-12-31 0000725394 us-gaap:NoncontrollingInterestMember 2025-10-01 2025-12-31 0000725394 us-gaap:RetainedEarningsMember 2025-07-01 2025-12-31 0000725394 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-07-01 2025-12-31 0000725394 DHTI:TotalDalradaFinancialCorpsStockholdersDeficitMember 2025-07-01 2025-12-31 0000725394 us-gaap:NoncontrollingInterestMember 2025-07-01 2025-12-31 0000725394 DHTI:PreferredStockSeriesIMember 2025-12-31 0000725394 DHTI:PreferredStockSeriesHMember 2025-12-31 0000725394 DHTI:PreferredStockSeriesGMember 2025-12-31 0000725394 DHTI:PreferredStockSeriesFMember 2025-12-31 0000725394 us-gaap:CommonStockMember 2025-12-31 0000725394 DHTI:CommonStockToBeIssuedMember 2025-12-31 0000725394 DHTI:PreferredStockToBeIssuedMember 2025-12-31 0000725394 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0000725394 us-gaap:RetainedEarningsMember 2025-12-31 0000725394 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-12-31 0000725394 DHTI:TotalDalradaFinancialCorpsStockholdersDeficitMember 2025-12-31 0000725394 us-gaap:NoncontrollingInterestMember 2025-12-31 0000725394 2024-06-30 0000725394 2024-12-31 0000725394 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember DHTI:HealthcareInsurersAndGovernmentPayersMember 2025-10-01 2025-12-31 0000725394 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember DHTI:HealthcareInsurersAndGovernmentPayersMember 2024-10-01 2024-12-31 0000725394 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember DHTI:HealthcareInsurersAndGovernmentPayersMember 2025-07-01 2025-12-31 0000725394 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember DHTI:HealthcareInsurersAndGovernmentPayersMember 2024-07-01 2024-12-31 0000725394 DHTI:HealthcareInsurersAndGovernmentPayersMember 2025-12-31 0000725394 DHTI:HealthcareInsurersAndGovernmentPayersMember 2025-06-30 0000725394 DHTI:CashlessWarrantsMember 2025-07-01 2025-12-31 0000725394 DHTI:CashlessWarrantsMember 2024-07-01 2024-12-31 0000725394 us-gaap:FairValueInputsLevel1Member DHTI:ContingentConsiderationMember 2025-12-31 0000725394 us-gaap:FairValueInputsLevel2Member DHTI:ContingentConsiderationMember 2025-12-31 0000725394 us-gaap:FairValueInputsLevel3Member DHTI:ContingentConsiderationMember 2025-12-31 0000725394 DHTI:ContingentConsiderationMember 2025-12-31 0000725394 us-gaap:FairValueInputsLevel1Member 2025-12-31 0000725394 us-gaap:FairValueInputsLevel2Member 2025-12-31 0000725394 us-gaap:FairValueInputsLevel3Member 2025-12-31 0000725394 us-gaap:FairValueInputsLevel1Member DHTI:ContingentConsiderationMember 2025-06-30 0000725394 us-gaap:FairValueInputsLevel2Member DHTI:ContingentConsiderationMember 2025-06-30 0000725394 us-gaap:FairValueInputsLevel3Member DHTI:ContingentConsiderationMember 2025-06-30 0000725394 DHTI:ContingentConsiderationMember 2025-06-30 0000725394 us-gaap:FairValueInputsLevel1Member 2025-06-30 0000725394 us-gaap:FairValueInputsLevel2Member 2025-06-30 0000725394 us-gaap:FairValueInputsLevel3Member 2025-06-30 0000725394 DHTI:ComputerAndOfficeEquipmentMember 2025-07-01 2025-12-31 0000725394 us-gaap:MachineryAndEquipmentMember 2025-07-01 2025-12-31 0000725394 us-gaap:LeaseholdImprovementsMember 2025-07-01 2025-12-31 0000725394 DHTI:ProductSalesThirdPartiesMember 2025-10-01 2025-12-31 0000725394 DHTI:ProductSalesThirdPartiesMember 2024-10-01 2024-12-31 0000725394 DHTI:ProductSalesThirdPartiesMember 2025-07-01 2025-12-31 0000725394 DHTI:ProductSalesThirdPartiesMember 2024-07-01 2024-12-31 0000725394 DHTI:ProductSalesRelatedPartyMember 2025-10-01 2025-12-31 0000725394 DHTI:ProductSalesRelatedPartyMember 2024-10-01 2024-12-31 0000725394 DHTI:ProductSalesRelatedPartyMember 2025-07-01 2025-12-31 0000725394 DHTI:ProductSalesRelatedPartyMember 2024-07-01 2024-12-31 0000725394 DHTI:ServiceRevenueThirdPartiesMember 2025-10-01 2025-12-31 0000725394 DHTI:ServiceRevenueThirdPartiesMember 2024-10-01 2024-12-31 0000725394 DHTI:ServiceRevenueThirdPartiesMember 2025-07-01 2025-12-31 0000725394 DHTI:ServiceRevenueThirdPartiesMember 2024-07-01 2024-12-31 0000725394 DHTI:ServiceRevenueRelatedPartyMember 2025-10-01 2025-12-31 0000725394 DHTI:ServiceRevenueRelatedPartyMember 2024-10-01 2024-12-31 0000725394 DHTI:ServiceRevenueRelatedPartyMember 2025-07-01 2025-12-31 0000725394 DHTI:ServiceRevenueRelatedPartyMember 2024-07-01 2024-12-31 0000725394 DHTI:ProductSalesMember 2025-10-01 2025-12-31 0000725394 DHTI:ProductSalesMember 2024-10-01 2024-12-31 0000725394 DHTI:ProductSalesMember 2025-07-01 2025-12-31 0000725394 DHTI:ProductSalesMember 2024-07-01 2024-12-31 0000725394 us-gaap:ServiceMember 2025-10-01 2025-12-31 0000725394 us-gaap:ServiceMember 2024-10-01 2024-12-31 0000725394 us-gaap:ServiceMember 2025-07-01 2025-12-31 0000725394 us-gaap:ServiceMember 2024-07-01 2024-12-31 0000725394 DHTI:GrandEntrancesPurchaseAgreementMember 2024-08-21 0000725394 DHTI:GrandEntrancesMember 2024-08-21 0000725394 DHTI:GrandEntrancesMember 2024-08-20 2024-08-21 0000725394 DHTI:CurriculumDevelopmentMember 2025-06-30 0000725394 us-gaap:LicenseMember 2025-06-30 0000725394 us-gaap:CustomerRelationshipsMember 2025-06-30 0000725394 us-gaap:TrademarksMember 2025-06-30 0000725394 DHTI:DevelopedTechnologySoftwareAndOtherMember 2025-06-30 0000725394 DHTI:CurriculumDevelopmentMember 2025-07-01 2025-12-31 0000725394 us-gaap:LicenseMember 2025-07-01 2025-12-31 0000725394 us-gaap:CustomerRelationshipsMember 2025-07-01 2025-12-31 0000725394 us-gaap:TrademarksMember 2025-07-01 2025-12-31 0000725394 DHTI:DevelopedTechnologySoftwareAndOtherMember 2025-07-01 2025-12-31 0000725394 DHTI:CurriculumDevelopmentMember 2025-12-31 0000725394 us-gaap:LicenseMember 2025-12-31 0000725394 us-gaap:CustomerRelationshipsMember 2025-12-31 0000725394 us-gaap:TrademarksMember 2025-12-31 0000725394 DHTI:DevelopedTechnologySoftwareAndOtherMember 2025-12-31 0000725394 DHTI:LoanAgreementMember DHTI:BandyRanchDevelopmentLLCMember 2025-09-29 2025-10-02 0000725394 DHTI:LoanAgreementMember DHTI:BandyRanchDevelopmentLLCMember 2025-10-02 0000725394 DHTI:RelatedEntity2Member 2025-12-31 0000725394 DHTI:RelatedEntity4Member 2025-12-31 0000725394 DHTI:RelatedEntity6Member 2025-12-31 0000725394 DHTI:RelatedEntity2Member 2025-06-30 0000725394 DHTI:RelatedEntity4Member 2025-06-30 0000725394 DHTI:RelatedEntity6Member 2025-06-30 0000725394 DHTI:IHGMember DHTI:EIDLLoanMember 2025-12-31 0000725394 DHTI:IHGMember DHTI:EIDLLoanMember 2025-06-30 0000725394 DHTI:COVID19GovernmentLoanMember 2025-12-31 0000725394 DHTI:COVID19GovernmentLoanMember DHTI:LikidoMember 2025-12-31 0000725394 DHTI:COVID19GovernmentLoanMember DHTI:LikidoMember 2025-06-30 0000725394 DHTI:COVID19GovernmentLoan1Member 2025-12-31 0000725394 DHTI:COVID19GovernmentLoan1Member 2024-12-31 0000725394 DHTI:COVID19GovernmentLoan1Member 2025-07-01 2025-12-31 0000725394 DHTI:COVID19GovernmentLoan1Member 2023-06-26 0000725394 DHTI:COVID19GovernmentLoan1Member 2023-06-30 0000725394 DHTI:COVID19GovernmentLoanMember 2023-06-29 2023-06-30 0000725394 DHTI:COVID19GovernmentLoan1Member 2025-11-21 0000725394 DHTI:OnPointLTBLLCMember 2023-07-25 0000725394 DHTI:OnPointLTBLLCMember 2023-07-24 2023-07-25 0000725394 DHTI:OnPointLTBLLCMember 2023-10-03 2023-10-04 0000725394 DHTI:OnPointLTBLLCMember 2025-12-31 0000725394 DHTI:NewCoCapitalGroupLLCMember 2024-01-03 2024-01-04 0000725394 DHTI:NewCoCapitalGroupLLCMember 2024-01-04 0000725394 2024-01-21 2024-01-22 0000725394 DHTI:CreditLineCapitalGroupMember 2024-05-01 2024-05-02 0000725394 DHTI:CreditLineCapitalGroupMember 2024-05-02 0000725394 DHTI:CreditLineCapitalGroupMember 2025-12-31 0000725394 DHTI:DiagonalLendingLLC1800Member 2024-05-16 0000725394 DHTI:DiagonalLendingLLC1800Member 2024-05-15 2024-05-16 0000725394 DHTI:AgileCapitalFundingLLCMember 2024-05-16 0000725394 DHTI:AgileCapitalFundingLLCMember 2024-05-15 2024-05-16 0000725394 DHTI:CucumberCapitalLLCMember 2024-06-24 2024-06-25 0000725394 DHTI:CucumberCapitalLLCMember 2024-06-25 0000725394 DHTI:RevenuePurchaseAgreementMember DHTI:TycoonCapitalGroupMember 2024-07-29 0000725394 DHTI:RevenuePurchaseAgreementMember DHTI:QuickFundingMember 2024-08-23 0000725394 DHTI:RevenuePurchaseAgreementMember DHTI:QFSCapitalLLCMember 2024-09-20 0000725394 DHTI:QFSCapitalLLCMember 2025-12-31 0000725394 DHTI:VanquishFundingGroupMember 2025-09-18 0000725394 DHTI:VanquishFundingGroupMember 2025-09-17 2025-09-18 0000725394 DHTI:VanquishFundingGroupMember 2025-12-31 0000725394 DHTI:AMFTeamInc.Member 2025-11-05 2025-11-06 0000725394 DHTI:AMFTeamInc.Member 2025-11-06 0000725394 DHTI:AMFTeamInc.Member 2025-12-31 0000725394 DHTI:FlowCapitalFundingMember 2025-11-13 2025-11-14 0000725394 DHTI:FlowCapitalFundingMember 2025-11-14 0000725394 DHTI:FlowCapitalFundingMember 2025-12-31 0000725394 DHTI:QuickFundingGroupMember 2025-11-13 2025-11-14 0000725394 DHTI:QuickFundingGroupMember 2025-11-14 0000725394 DHTI:QuickFundingGroupMember 2025-12-31 0000725394 DHTI:VanquishFundingGroup1Member 2025-11-17 0000725394 DHTI:VanquishFundingGroup1Member 2025-11-16 2025-11-17 0000725394 DHTI:VanquishFundingGroup1Member 2025-12-31 0000725394 DHTI:VerveFundingMember 2025-12-15 2025-12-16 0000725394 DHTI:VerveFundingMember 2025-12-16 0000725394 DHTI:VerveFundingMember 2025-12-31 0000725394 DHTI:AlphaEquityFundMember 2025-12-15 2025-12-16 0000725394 DHTI:AlphaEquityFundMember 2025-12-16 0000725394 DHTI:AlphaEquityFundMember 2025-12-31 0000725394 DHTI:MCIGroupLLCdbaCCMember 2025-12-21 2025-12-22 0000725394 DHTI:MCIGroupLLCdbaCCMember 2025-12-22 0000725394 DHTI:MCIGroupLLCdbaCCMember 2025-12-31 0000725394 DHTI:RelatedPartyDebtMember 2024-06-29 2024-06-30 0000725394 DHTI:RelatedPartyDebtMember DHTI:SeriesIPreferredStockMember 2024-06-29 2024-06-30 0000725394 DHTI:RelatedPartyDebtMember 2025-06-24 2025-06-25 0000725394 DHTI:RelatedPartyDebtMember DHTI:SeriesIPreferredStockMember 2025-06-24 2025-06-25 0000725394 DHTI:RelatedPartiesMember 2025-12-31 0000725394 DHTI:RelatedPartiesMember 2025-06-30 0000725394 DHTI:CashFromRelatedPartiesMember 2024-07-01 2025-06-30 0000725394 DHTI:CashFromRelatedPartiesMember 2025-06-30 0000725394 DHTI:BothofBrothersMember DHTI:ConstructionServicesMember 2024-07-01 2025-06-30 0000725394 DHTI:BothofBrothersMember DHTI:CustomDoorSalesMember 2024-07-01 2025-06-30 0000725394 DHTI:CashFromRelatedPartiesMember 2025-09-30 0000725394 DHTI:BothofBrothersMember 2025-10-01 2025-12-31 0000725394 DHTI:BothofBrothersMember 2024-10-01 2024-12-31 0000725394 DHTI:BothofBrothersMember 2025-07-01 2025-12-31 0000725394 DHTI:BothofBrothersMember 2024-07-01 2024-12-31 0000725394 DHTI:RelatedPartyPrincipalAndInterestMember DHTI:SeriesIConvertiblePreferredStockMember 2024-03-28 2024-03-29 0000725394 DHTI:AcquisitionAgreementMember DHTI:SiliconServicesConsortiumLtd.Member 2022-04-06 0000725394 DHTI:AcquisitionAgreementMember DHTI:SiliconServicesConsortiumLtd.Member 2022-04-05 2022-04-07 0000725394 DHTI:AcquisitionAgreementMember DHTI:SiliconServicesConsortiumLtd.Member 2022-04-07 0000725394 DHTI:SeriesIConvertiblePreferredStockMember 2024-05-21 2024-05-22 0000725394 DHTI:RelatedPartyPrincipalAndInterestMember DHTI:SeriesIPreferredStockMember 2024-06-29 2024-06-30 0000725394 DHTI:SeriesIPreferredStockMember 2024-10-02 2024-10-03 0000725394 DHTI:SeriesIPreferredStockMember 2024-10-03 0000725394 DHTI:SeriesIPreferredStockMember DHTI:SeriesIConvertedIntoCommonStockMember 2024-10-13 2024-10-14 0000725394 us-gaap:CommonStockMember DHTI:SeriesIConvertedIntoCommonStockMember 2024-10-13 2024-10-14 0000725394 DHTI:RelatedPartyPrincipalAndInterestMember DHTI:SeriesIPreferredStockMember 2025-06-24 2025-06-25 0000725394 DHTI:ConsultantMember 2025-02-01 2025-02-28 0000725394 2023-07-01 2024-06-30 0000725394 2024-07-01 2025-06-30 0000725394 DHTI:GeneficMember 2025-10-01 2025-12-31 0000725394 DHTI:DalradaClimateTechnologyMember 2025-10-01 2025-12-31 0000725394 DHTI:DalradaPrecisionManufacturingMember 2025-10-01 2025-12-31 0000725394 DHTI:DalradaTechnologiesMember 2025-10-01 2025-12-31 0000725394 us-gaap:CorporateMember 2025-10-01 2025-12-31 0000725394 DHTI:GeneficMember 2024-10-01 2024-12-31 0000725394 DHTI:DalradaClimateTechnologyMember 2024-10-01 2024-12-31 0000725394 DHTI:DalradaPrecisionManufacturingMember 2024-10-01 2024-12-31 0000725394 DHTI:DalradaTechnologiesMember 2024-10-01 2024-12-31 0000725394 us-gaap:CorporateMember 2024-10-01 2024-12-31 0000725394 DHTI:GeneficMember 2025-07-01 2025-12-31 0000725394 DHTI:DalradaClimateTechnologyMember 2025-07-01 2025-12-31 0000725394 DHTI:DalradaPrecisionManufacturingMember 2025-07-01 2025-12-31 0000725394 DHTI:DalradaTechnologiesMember 2025-07-01 2025-12-31 0000725394 us-gaap:CorporateMember 2025-07-01 2025-12-31 0000725394 DHTI:GeneficMember 2024-07-01 2024-12-31 0000725394 DHTI:DalradaClimateTechnologyMember 2024-07-01 2024-12-31 0000725394 DHTI:DalradaPrecisionManufacturingMember 2024-07-01 2024-12-31 0000725394 DHTI:DalradaTechnologiesMember 2024-07-01 2024-12-31 0000725394 us-gaap:CorporateMember 2024-07-01 2024-12-31 0000725394 country:US 2025-07-01 2025-12-31 0000725394 country:US 2024-07-01 2024-12-31 0000725394 country:GB 2025-07-01 2025-12-31 0000725394 country:GB 2024-07-01 2024-12-31 0000725394 country:ES 2025-07-01 2025-12-31 0000725394 country:ES 2024-07-01 2024-12-31 0000725394 country:IN 2025-07-01 2025-12-31 0000725394 country:IN 2024-07-01 2024-12-31 0000725394 country:US 2025-12-31 0000725394 country:US 2025-06-30 0000725394 country:GB 2025-12-31 0000725394 country:GB 2025-06-30 0000725394 country:ES 2025-12-31 0000725394 country:ES 2025-06-30 0000725394 country:IN 2025-12-31 0000725394 country:IN 2025-06-30 0000725394 DHTI:PortlandMember 2024-08-31 0000725394 DHTI:SanDiegoCaliforniaMember 2024-10-31 0000725394 DHTI:IVPharmaceuticalServicesMember 2025-07-31 0000725394 DHTI:AssetGroupIncMember DHTI:DalradaHealthProductsMember 2023-09-30 0000725394 DHTI:MDIQMember DHTI:DalradaHealthProductsMember 2024-03-31 0000725394 DHTI:DFCOMember 2024-11-18 2024-11-19 0000725394 DHTI:FFFEnterprisesMember DHTI:GeneficAndDFCOMember 2024-11-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure DHTI:Integer

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 2025

☐ TRANSITION REPORT UNDER SECTION 13 OR 15 (d) OF THE EXCHANGE ACT

For the transition period from _________ to _________

Commission File Number: 000-12641

DALRADA TECHNOLOGY GROUP, INC.

(Name of Small Business Issuer in its charter)

Wyoming	38-3713274
(state or other jurisdiction of incorporation or organization)	(I.R.S. Employer ID. No.)

600 La Terraza Blvd., Escondido, California 92025

(Address of principal executive offices)

858-283-1253

Issuer’s telephone number

Securities registered pursuant to Section 12(b) of the Act: Not applicable

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Securities registered pursuant to Section 12(g) of the Act: Common Stock, $0.005 par value per share

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐		Accelerated filer ☐
Non-accelerated filer ☒		Smaller reporting company ☒
		Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act) Yes ☐ No ☒

As of February 20, 2026, the registrant’s outstanding stock consisted of 120,157,113 common shares.

DALRADA TECHNOLOGY GROUP, INC.

Table of Contents

PART I – FINANCIAL INFORMATION	3

Item 1. Condensed Consolidated Financial Statements	3

Condensed Consolidated Balance Sheets	3
Condensed Consolidated Statements of Operations and Comprehensive Loss	4
Condensed Consolidated Statements of Stockholders’ Equity (Deficit)	5
Condensed Consolidated Statements of Cash Flows	8
Notes to the Condensed Consolidated Financial Statements	9

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	37
Item 3. Quantitative and Qualitative Disclosures About Market Risk	44
Item 4. Controls and Procedures	44

PART II – OTHER INFORMATION	45

Item 1. Legal Proceedings	45
Item 1A. Risk Factors	46
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds Securities	46
Item 3. Defaults Upon Senior Securities	46
Item 4. Mine Safety Disclosures	46
Item 5. Other Information	46
Item 6. Exhibits	46

SIGNATURES	47

PART I – FINANCIAL INFORMATION

Item 1. Unaudited Interim Condensed Consolidated Financial Statements.

DALRADA TECHNOLOGY GROUP, INC.

Consolidated Balance Sheets (unaudited)


	December 31,			June 30,
	2025			2025
	(Unaudited)
Assets
Current assets:
Cash and cash equivalents	$	70,074		$	172,787
Restricted cash		329,307			329,307
Accounts receivable, net		2,092,232			2,747,194
Accounts receivable, net - related parties		1,318,508			1,093,620
Inventories		2,718,050			2,689,845
Prepaid expenses and other current assets		641,770			708,268
Total current assets		7,169,941			7,741,021
Long-term receivables		–			18,261
Long-term receivables - related parties		1,464,132			913,036
Property and equipment, net		1,084,051			1,273,315
Goodwill		1,529,187			1,531,893
Intangible assets, net		2,915,190			3,110,826
Right-of-use asset, net - Operating		2,538,923			2,629,794
Right-of-use asset, net - related party - Operating		885,798			1,140,749
Total assets	$	17,587,222		$	18,358,895

Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	4,545,589		$	4,175,896
Accrued liabilities		2,158,160			1,256,451
Accounts payable and accrued liabilities – related parties		8,583,606			3,387,977
Deferred revenue		1,616,653			1,506,686
Notes payable, current portion		4,096,187			3,937,797
Notes payable, net of current portion – related parties		–			–
Lease Liability, current portion - Operating		890,237			899,402
Lease Liability, current portion - related - Operating		620,523			578,631
Total current liabilities		22,510,955			15,742,840
Noncurrent payables
Notes payable, net of current portion		5,028,437			4,926,416
Notes payable, net of current portion – related parties		4,640,311			1,701,415
Contingent consideration		211,289			211,289
Lease Liability, net of current portion - Operation		1,789,962			1,850,671
Lease Liability, net of current portion - related party - Operating		309,642			614,681
Total liabilities		34,490,596			25,047,312

Commitments and contingencies (Note 12)		–			–

Stockholders’ equity (deficit):
Series I preferred stock, $0.01 par value, 100,000 shares authorized, 69,965 and 55,759 shares issued and outstanding as of December 31, 2025 and June 30, 2025, respectively		700			558
Series H preferred stock, $0.01 par value, 15,002 shares authorized, issued and outstanding as of December 31, 2025 and June 30, 2025, respectively		150			150
Series G preferred stock, $0.01 par value, 100,000 shares authorized, 10,002 shares issued and outstanding as of both December 31, 2025 and June 30, 2025, respectively		100			100
Series F preferred stock, $0.01 par value, 5,000 shares authorized, issued and outstanding as of both December 31, 2025 and June 30, 2025, respectively		50			50
Common stock, $0.005 par value, 500,000,000 shares authorized, 120,157,113 and 120,157,113 shares issued and outstanding at December 31, 2025 and June 30, 2025, respectively		600,785			600,785
Common stock to be issued		14,650			7,265
Preferred stock to be issued		–			11,861,578
Additional paid-in capital		188,398,749			176,249,788
Accumulated deficit		(205,800,655	)		(195,323,647	)
Accumulated other comprehensive loss		9,450			(150,536	)
Total Dalrada Technology Group’s stockholders’ equity (deficit)		(16,776,021	)		(6,753,909	)
Noncontrolling interests		(127,353	)		65,492
Total stockholders’ equity (deficit)		(16,903,374	)		(6,688,417	)
Total liabilities and stockholders’ equity	$	17,587,222		$	18,358,895

(The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements)

DALRADA TECHNOLOGY GROUP, INC.

Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)


	Three Months Ended						Six Months Ended
	December 31,						December 31,
	2025			2024			2025			2024
Revenues	$	3,257,307		$	2,808,028		$	6,777,371		$	8,619,735
Revenues - related party		2,626			306,830			581,348			525,778
Total revenues		3,259,933			3,114,858			7,358,719			9,145,513
Cost of revenues		2,135,036			2,279,976			5,673,644			7,147,464
Gross profit		1,124,897			834,882			1,685,075			1,998,049

Operating expenses:
Selling, general and administrative		4,698,209			5,880,763			10,577,651			12,766,004
Total operating expenses		4,698,209			5,880,763			10,577,651			12,766,004
Loss from operations		(3,573,312	)		(5,045,881	)		(8,892,576	)		(10,767,955	)

Other income (expense):
Interest expense		(844,780	)		(1,033,800	)		(1,578,118	)		(2,099,614	)
Interest income		2,643			22,159			5,056			40,282
Other expense		1,670			(747,891	)		3,430			(782,925	)
Gain (loss) on foreign exchange		3,697			65,774			738			71,659
Total other expense, net		(836,770	)		(1,693,758	)		(1,568,894	)		(2,770,598	)
Loss before taxes		(4,410,082	)		(6,739,639	)		(10,461,470	)		(13,538,553	)
Income Taxes		(14,500	)		(7,524	)		(26,180	)		(7,524	)
Net loss		(4,424,582	)		(6,747,163	)		(10,487,650	)		(13,546,077	)

Other comprehensive loss
Foreign currency translation		147,828			69,329			159,986			49,654
Comprehensive loss	$	(4,276,754	)	$	(6,677,834	)	$	(10,327,664	)	$	(13,496,423	)

Net loss attributable to noncontrolling interests	$	(6,975	)	$	(37,562	)	$	(10,642	)	$	(25,477	)
Net loss attributable to Dalrada Technology Group Inc. stockholders	$	(4,417,607	)	$	(6,709,601	)	$	(10,477,008	)	$	(13,520,600	)

Net loss per common share to Dalrada stockholders – basic	$	(0.04	)	$	(0.07	)	$	(0.10	)	$	(0.15	)
Net loss per common share to Dalrada stockholders – diluted	$	(0.04	)	$	(0.07	)	$	(0.10	)	$	(0.15	)

Weighted average common shares outstanding – basic		108,488,220			92,934,331			108,488,220			92,135,080
Weighted average common shares outstanding – diluted		108,488,220			92,934,331			108,488,220			92,135,080

(The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements)

DALRADA TECHNOLOGY GROUP, INC.

Condensed Consolidated Statements of Changes in Stockholders’ Equity (Deficit) (unaudited)

Preferred Stock

Series I

Series H

Series G

Series F

Amount

Balance at June 30, 2025

55,759

558

15,022

150

10,002

100

5,000

Common stock issued pursuant to acquisitions

–

Conversion of related party notes into preferred stock

–

Warrants issued pursuant to acquisitions

–

Common stock issued pursuant to consulting agreement

–

Stock-based compensation

–

Removal of NCI retained upon closure of Pala

–

Net loss

–

Foreign currency translation

–

Balance at September 30, 2025

55,759

558

15,022

150

10,002

100

5,000

Common stock issued pursuant to acquisitions

–

Conversion of related party notes into preferred stock

14,206

142

–

Warrants issued pursuant to acquisitions

–

Common stock issued pursuant to consulting agreement

–

Stock-based compensation

–

Net loss

–

Foreign currency translation

–

Balance at December 31, 2025

69,965

700

15,022

150

10,002

100

5,000

Balance at June 30, 2025

55,759

558

15,022

150

10,002

100

5,000

Common stock issued pursuant to acquisitions

–

Conversion of related party notes into preferred stock

14,206

142

–

Warrants issued pursuant to acquisitions

–

Common stock issued pursuant to consulting agreement

–

Stock-based compensation

–

Removal of NCI retained upon closure of Pala

–

Net loss

–

Foreign currency translation

–

Balance at December 31, 2025

69,965

700

15,022

150

10,002

100

5,000

(The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements)

DALRADA TECHNOLOGY GROUP, INC.

Condensed Consolidated Statements of Changes in Stockholders’ Equity (Deficit) (unaudited)

(continued)

Common Stock

Preferred Stock

Additional Paid-in

Amount

to be Issued

Capital

Balance at June 30, 2025

120,157,113

600,785

7,265

11,861,578

176,249,788

Common stock issued pursuant to acquisitions

–

Conversion of related party notes into preferred stock

–

Warrants issued pursuant to acquisitions

–

5,749

Common stock issued pursuant to consulting agreement

–

3,692

–

Stock-based compensation

–

131,250

Removal of NCI retained upon closure of Pala

–

Net loss

–

Foreign currency translation

–

Balance at September 30, 2025

120,157,113

600,785

10,957

11,861,578

176,386,787

Common stock issued pursuant to acquisitions

–

Warrants issued pursuant to acquisitions

–

5,748

Conversion of related party notes into preferred stock

–

(11,861,578

)

11,861,436

Common stock issued pursuant to consulting agreement

–

3,693

–

Stock-based compensation

–

144,778

Net loss

–

Foreign currency translation

–

Balance at December 31, 2025

120,157,113

600,785

14,650

–

188,398,749

Balance at June 30, 2025

120,157,113

600,785

7,265

11,861,578

176,249,788

Common stock issued pursuant to acquisitions

–

Conversion of related party notes into preferred stock

–

(11,861,578

)

11,861,436

Warrants issued pursuant to acquisitions

–

11,497

Common stock issued pursuant to consulting agreement

–

7,385

–

Stock-based compensation

–

276,028

Removal of NCI retained upon closure of Pala

–

Net loss

–

Foreign currency translation

–

Balance at December 31, 2025

120,157,113

600,785

14,650

–

188,398,749

(The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements)

DALRADA TECHNOLOGY GROUP, INC.

Condensed Consolidated Statements of Changes in Stockholders’ Equity (Deficit) (unaudited)

(continued)


				Accumulated Other Comprehensive			Total Dalrada Financial Corp's						Total Stockholders’
	Accumulated			Income			Stockholders'			Noncontrolling			Equity
	Deficit			(Loss)			Deficit			Interests			(Deficit)

Balance at June 30, 2025	$	(195,323,647	)	$	(150,536	)	$	(6,753,909	)	$	65,492		$	(6,688,417	)
Common stock issued pursuant to acquisitions		–			–			–			–			–
Conversion of related party notes into preferred stock		–			–			–			–			–
Warrants issued pursuant to acquisitions		–			–			5,749			–			5,749
Common stock issued pursuant to consulting agreement		–			–			3,692			–			3,692
Stock-based compensation		–			–			131,250			–			131,250
Removal of NCI retained upon closure of Pala		–			–			–			–			–
Net loss		(6,059,401	)		–			(6,059,401	)		(3,667	)		(6,063,068	)
Foreign currency translation		–			12,158			12,158			–			12,158
Balance at September 30, 2025	$	(201,383,048	)	$	(138,378	)	$	(12,660,461	)	$	61,825		$	(12,598,636	)
Common stock issued pursuant to acquisitions		–			–			–			–			–
Warrants issued pursuant to acquisitions		–			–			5,748			–			5,748
Common stock issued pursuant to consulting agreement		–			–			3,693			–			3,693
Stock-based compensation		–			–			144,778			–			144,778
Net loss		(4,417,607	)		–			(4,417,607	)		(189,178	)		(4,606,785	)
Foreign currency translation		–			147,828			147,828			–			147,828
Balance at December 31, 2025	$	(205,800,655	)	$	9,450		$	(16,776,021	)	$	(127,353	)	$	(16,903,374	)



Balance at June 30, 2025		(195,323,647	)		(150,536	)		(6,753,909	)		65,492			(6,688,417	)
Common stock issued pursuant to acquisitions		–			–			–			–			–
Conversion of related party notes into preferred stock		–			–			–			–			–
Warrants issued pursuant to acquisitions		–			–			11,497			–			11,497
Common stock issued pursuant to consulting agreement		–			–			7,385			–			7,385
Stock-based compensation		–			–			276,028			–			276,028
Removal of NCI retained upon closure of Pala		–			–			–			–			–
Net loss		(10,477,008	)		–			(10,477,008	)		(192,845	)		(10,669,853	)
Foreign currency translation		–			159,986			159,986			–			159,986
Balance at December 31, 2025	$	(205,800,655	)	$	9,450		$	(16,776,021	)	$	(127,353	)	$	(16,903,374	)

(The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements)

DALRADA TECHNOLOGY GROUP, INC.

Condensed Consolidated Statements of Cash Flows (unaudited)


	Six Months Ended December 31,
	2025			2024
Cash flows from operating activities:
Net loss	$	(10,487,650	)	$	(13,546,077	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		409,731			496,346
Stock compensation		290,800			1,383,026
Changes in operating assets and liabilities, net of amounts acquired or assumed in connection with acquisition:
Accounts receivable		430,074			1,448,549
Other receivables		17,109			476,542
Inventories		(28,205	)		20,869
Prepaid expenses and other current assets		49,389			11,308
Noncurrent receivables		–			20,038
Long-term receivables		(532,835	)		(770,154	)
Accounts payable and accrued liabilities - related parties		5,565,322			6,353,306
Accrued liabilities		901,709			(290,362	)
Decrease in Right of Use Asset/Liability		12,801			21,209
Contingent consideration		–			208,339
Deferred revenue		109,967			(266,541	)
Net cash used in operating activities		(3,261,788	)		(4,433,602	)
Cash flows from investing activities:
Purchase of property and equipment		–			(268,728	)
Purchase of intangibles		–			(146,449	)
Acquisition of business, net of cash		–			(42,108	)
Net cash used in investing activities		–			(457,285	)
Cash flows from financing activities:
Net proceeds (repayments) from related party notes payable		2,441,062			2,367,759
Repayments of notes payable		–			–
Net proceeds (repayments) from notes payable		260,411			1,329,634
Additional Paid in Capital		12,148,961			666,806
Stock issued		(11,854,051	)		114,863
Net cash provided by financing activities		2,996,383			4,479,062
Net change in cash and cash equivalents		(265,405	)		(411,825	)
Effect of exchange rate changes on cash		162,692			49,654
Cash and cash equivalents at beginning of period		502,094			501,927
Cash and cash equivalents at end of period	$	399,381		$	139,756

Supplemental disclosure of cash flow information:
Cash paid for income taxes	$	18,680		$	11,600
Cash paid for interest	$	205,384		$	2,099,614

Supplemental disclosure of non-cash investing and financing activities:
Conversion of related party notes and interest into preferred stock	$	–		$	17,243,235
Preferred stock issued pursuant to business combination	$	–		$	4,596,290
Warrants issued pursuant to acquisitions	$	11,496		$	11,496
(Decrease) Increase in right-of-use asset and liability	$	(4,848	)	$	(21,209	)

(The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements)

DALRADA TECHNOLOGY GROUP, INC.

Notes to the Condensed Consolidated Financial Statements (unaudited)

1.	Organization and Nature of Operations

Unless otherwise stated or the context requires otherwise, references herein to the “Company,” “Dalrada,” “we,” “us,” and “our” mean Dalrada Technology Group, Inc. and its direct and indirect subsidiaries, and controlled and managed entities.

Dalrada has five primary business divisions: Genefic, Dalrada Climate Technology, Dalrada Precision Manufacturing, Dalrada Technologies and Dalrada Corporate. Within each of these divisions, the Company seeks to drive innovation while creating solutions that are sustainable, accessible, and affordable. Dalrada’s global solutions directly address climate change, gaps in the health care industry, and technology needs that facilitate a new era of human behavior and interaction and ensure a bright future for the world around us.

Genefic

Genefic delivers advanced health care solutions with dedicated products, services, and systems. From virus and disease screening capabilities to pharmaceutical goods and holistic wellness clinics, When the world needs advanced health care, Genefic delivers with ingenuity, accessibility, and affordability. This specialized division is committed to developing key health products, lifesaving medications and building comprehensive systems to increase capability, striving to keep people healthy with the goals of improving their quality of life and increasing their longevity on a global level.

Genefic Specialty Pharmacy (“Genefic Pharmacy”)- Genefic Pharmacy (formerly Genefic Specialty Pharmacy Rx Solutions) is an Alabama-based pharmacy with more than 30 years of experience in the retail medical and pharmaceutical industries. Genefic Pharmacy specializes in providing expert care and managing disease states through comprehensive prescription management, education, nursing, and total health solutions. Genefic Pharmacy maintains pharmacy licenses in all 50 States as well as Washington D.C.

Genefic Infusion Rx- Genefic Infusion Rx is a Louisiana-based infusion pharmacy which handles all aspects of fluid and medication infusion, via intravenous or subcutaneous application. Genefic Infusion Rx serves as an essential with healthcare systems, enhancing the infusion process through efficient authorization and prescription management. Its compounding facility is led by one of only eight pharmacists in Louisiana with a sterile compounding board certification, ensuring top-tier precision and quality in medication preparation.

Boost Diagnostics- Boost Diagnostics (formerly Empower Genomics and Genefic Diagnostics) is Dalrada’s wholly owned diagnostic laboratory subsidiary which processes molecular diagnostic and antibody tests to support the diagnosis of COVID-19 and the detection of immune response to the virus. Boost Diagnostics has built up and maintained the testing capacity to handle surges in COVID-19 testing demands. Boost Diagnostics also offers genetic testing capabilities including Pharmacogenomics, Nutraceutical, Nutrition/Diet DNA and Exercise/Fitness DNA tests.

Dalrada Career Institute (“DCI”) (aka International Health Group (“IHG”)) - IHG provides highly trained nursing and medical assistants for hospitals and home health facilities since 2006. IHG Medical Assistant programs include Certified Nursing Assistant (“CNA”) and Home Health Aide (“HHA”) training and the fast-track 22-Day CNA Certification Program at its state-approved testing facility. DCI started its first RN, nursing class in February of 2024 and this first class will be completed in December 2024. It is the intent of DCI to double their class size when they begin their second class in 2025.

Dalrada Climate Technology (formerly Dalrada Energy Services)

Dalrada Climate Technology (“DCT”) is a segment which incapsulates energy services and technology within the climate sustainability space. DCT employs next-generation technology and services which enhances clean energy efforts while reducing the world’s carbon footprint. As a premier industrial heat pump manufacturer, Dalrada delivers innovation and efficiency, building solutions that reduce energy consumption and minimize carbon footprints, increase operational efficiencies, meet environmental, social, and governance (ESG) goals, and lower energy costs for clients.

Dalrada Technology Limited (“DTL”)- DTL is a holding company for all United Kingdom and European based Dalrada Climate Technology entities.

Likido Ltd. (“Likido”)- Likido is an international engineering company developing advanced solutions for the harvesting and recycling of energy. Using its novel, heat pump systems (patent pending), Likido is working to revolutionize the renewable energy sector with the provision of innovative modular process technologies to maximize the capture and reuse of thermal energy for integrated heating and cooling applications. With uses across industrial, commercial and residential sectors, Likido provides cost savings and minimized carbon emissions across global supply chains. Likido’s technologies enable the effective recovery and recycling of process energy, mitigating against climate change and expected enhancement of quality of life through the provision of low-carbon heating and cooling systems. Likido’s products currently include the DCT One Heat Pumps (formerly Likido®ONE) and DCT Cryo Chiller. Likido also offers heat pump solutions specifically designed for residential purposes.

During the prior year, the U.S. Government selected DCT One Series high-performance, low-carbon heat pump for real-world testing in a clean energy program. The implementation of the DCT One Series testing is still in process.

Dalrada Technology Spain L.T. (“DTS”)- DTS was established as a Spanish subsidiary of DTL for the expansion of the manufacturing and sale of the DCT One Series and DCT Cryo Chiller throughout Europe.

Dalrada Energy Services (“DES”)- DES provides end-to-end comprehensive energy service solutions in a robust commercial capacity. DES helps organizations meet ESG goals and standards while mitigating negative environmental impacts.

Bothof Brothers Construction (“Bothof”)- Bothof is a licensed general contractor which provides a wide range of development, construction and design capabilities and expertise throughout the United States. Through Bothof’s extensive experience in construction and contracting, the DES division can provide a myriad of additional services to its private and public works customers.

Grand Entrances- Grand Entrances is a California based custom door and hardware retail store.

Dalrada Precision Manufacturing

Dalrada Precision Manufacturing creates total manufacturing solutions that start with the design and development of high-quality machine parts and components, and end with an efficient global supply chain. This specialized business division can meet today’s high demands and solves industry challenges. Dalrada Precision Manufacturing is confident that it redefines the critical quality of the world’s top components and responds with in-house research, design, engineering, and distribution through a highly reliable global supply chain and improved time-to-market capabilities.

Dalrada Precision Parts (“Precision”) - Precision extends the client its engineering and operations team by helping devise unique manufacturing solutions tailored to their products. Dalrada Precision can enter at any stage of the product lifecycle from concept and design to mass production and logistics.

Deposition Technologies (“DepTec”) - DepTec designs, develops, manufactures, and services chemical vapor and physical vapor deposition systems for the microchip and semiconductor industries.

DepTec has built an impressive catalogue of precision OEM parts for PVD (Physical vapor deposition) systems and the Company’s refurbished systems which allows clients the option of purchasing the same model of system they’ve been using for decades –but with significant upgrades and improved efficiencies. Older systems can now operate more reliably with additional control and monitoring plus longer lifespans. DepTec also has its own PVD and CVD (Chemical Vapor Deposition) systems, EVOS-PVD and EVOS -CVD, which deposits metals and non-metals for microchips used in almost every standard and specialized microdevices made today and in the future. These systems can produce a superior film layer utilized in rugged high-stress environment designs.

Dalrada Technologies

Dalrada Technologies has worked with some of the world’s most recognizable companies, providing digital engineering for cutting-edge software systems and offering a host of robust digital services. This business division connects the world with integrated technology and innovative solutions, delivering advanced capabilities and error-free results. Dalrada Technologies creates digital products with expert computer information technology and software engineering services for a variety of technical industries and clients in both B2B and B2C environments.

Prakat (“Prakat”)- Prakat is an ISO 9001-certified company that provides end-to-end technology services across various industries, improving the value chain. The Company specializes in test engineering, accessibility engineering, product engineering, application modernization, billing and revenue management, CRM, and block chain. Prakat provides global customers with software and technology solutions specializing in Test Engineering, Accessibility Engineering, Product Engineering and Application Modernization.

Dalrada Corporate

Dalrada Corporate covers the activities which support the entire suite of Dalrada subsidiaries. Dalrada Corporate includes the areas of administration, finance, human resources, legal advice, information technology, and marketing. It also contains executive management and shareholder-related services.

Liquidity and Going Concern

These condensed consolidated financial statements have been prepared on a going concern basis, which implies that the Company will continue to realize its assets and discharge its liabilities in the normal course of business. As of December 31, 2025, and June 30, 2025, the Company had negative working capital of $15,341,014 and $8,001,819, respectively. The Company incurred negative cash flows from operations for the three months ended December 31, 2025, and 2024, and raises substantial doubt about our ability to continue as a going concern for the twelve-month period following the date of this report. The continuation of the Company as a going concern is dependent upon the successful financing through equity and/or debt investors and growing the subsidiaries anticipated to be profitable while reducing investments in areas that are not expected to have long-term benefits. The Company expects to obtain operational liquidity through collection of outstanding accounts receivable from medical insurance providers, the sale of DCT heat pumps as well as ongoing projects through the Company’s various subsidiaries.

2.	Summary of Significant Accounting Policies

(a)

Basis of Presentation

These unaudited interim condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) for interim financial information and in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”),. Accordingly, certain information and disclosures required by US GAAP for annual financial statements have been omitted. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. Unless otherwise indicated, balances are expressed in U.S. dollars. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto as of and for the year ended June 30, 2025 (the “2025 Annual Audited Financials”), included in the Company’s Annual Report on Form 10-K filed with the SEC on September 29, 2025 (the “Form 10-K”). The results of operations as of and for the three and six months ended December 31, 2025 are not necessarily indicative of the results to be expected for the 2025 full year or any future periods. The accompanying consolidated balance sheet as of June 30, 2025 has been derived from the audited consolidated balance sheet as of June 30, 2025 contained in the 2025 Annual Audited Financials included in the Form 10-K.

(b)

Principles of Consolidation

The unaudited interim condensed consolidated financial statements include the accounts of the Company and its subsidiaries, as well as the accounts of any entities over which the Company has a controlling financial interest in accordance with Accounting Standards Codification (“ASC”) 810 Consolidation. All transactions and balances between these entities have been eliminated upon consolidation.

Income attributable to the minority interest in the Company’s majority owned and controlled consolidated subsidiaries is recorded as net income attributable to noncontrolling interests in the condensed consolidated Statements of operations and comprehensive loss and the noncontrolling interest is reflected as a separate component of the condensed consolidated statements of stockholders’ equity, condensed consolidated balance sheets, and condensed consolidated statements of cash flows.

(c)

Use of Estimates

The preparation of these unaudited interim condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the revenue, valuation of inventory, valuation of acquired assets and liabilities, variables used in the computation of share-based compensation, litigation, contingent consideration, and evaluation of goodwill and intangible assets for impairment.

The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.

(d)

Cash and Cash Equivalents

Cash and cash equivalents include cash deposits in financial institutions, and the Company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents.

(e)

Concentrations of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, accounts receivable, and cash equivalents. The Company generally maintains balances in various operating accounts at financial institutions that management believes to be of high credit quality, in amounts that may exceed federally insured limits. The Company has not experienced any losses related to its cash and cash equivalents and does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.

When estimating its allowance for credit losses related to revenues from pharmaceutical sales, the Company differentiates its receivables based on the following customer types: healthcare insurers, government payers, and cash payers. Additionally, the Company applies assumptions and judgments for assessing collectability and determining net revenues and accounts receivable from its customers. Management considers various historical collection factors for assessing collectability and determining net revenues and accounts receivable from our customers which include the period that the receivables have been outstanding, history of payment amounts, status of collections due, and applicable statutes of limitations.

During the three months ended December 31, 2025, and 2024, healthcare insurers and government payers accounted for 27% and 46% of total revenues, respectively. During the six months ended December 31, 2025, and 2024, healthcare insurers and government payers accounted for 33% and 60% of total revenues, respectively. The accounts receivable related to both healthcare insurers and government payers are $623,299 and $781,756 as of December 31, 2025 and June 30, 2025, respectively.

(f)

Fair Value Measurements

Pursuant to ASC 820, Fair Value Measurements and Disclosures, an entity is required to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value:

Level 1 - applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

Level 2 - applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.

Level 3 - applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.

The Company’s financial instruments consist principally of cash, accounts receivable, accounts payable and accrued liabilities, notes payable, and amounts due to related parties. Pursuant to ASC 820, the fair value of cash is determined based on “Level 1” inputs, which consist of quoted prices in active markets for identical assets. The recorded values of all other financial instruments approximate their current fair values because of their nature and respective maturity dates or durations.

The fair value of the contingent consideration obligations was based on a probability weighted approach derived from the estimates of earn-out criteria and the probability assessment with respect to the likelihood of achieving those criteria. The measurement was based on significant inputs that were not observable in the market, therefore, the Company classified this liability as Level 3 in the following tables:

Schedule of fair value of liabilities
	Fair Value Measurements as of December 31, 2025:
	Level 1		Level 2		Level 3		Total
Liabilities:
Contingent consideration	$	–	$	–	$	211,289	$	211,289
	$	–	$	–	$	211,289	$	211,289

	Fair Value Measurements as of June 30, 2025:
	Level 1		Level 2		Level 3		Total
Liabilities:
Contingent consideration	$	–	$	–	$	211,289	$	211,289
	$	–	$	–	$	211,289	$	211,289

The fair value of the contingent consideration liability related to the Company’s business combinations is valued based on a forward contract and the guaranteed equity value at settlement as defined in the acquisition agreement (see “Note 3. Business Combinations and Asset Acquisition).

(g)

Convertible Instruments

The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC Topic 815, Derivatives and Hedging Activities (“ASC 815”).

Applicable U.S. GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria includes circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.

The Company accounts for convertible instruments (when the Company has determined that the embedded conversion options should not be bifurcated from their host instruments) as follows. The Company records, when necessary, deemed dividends for the intrinsic value of conversion options embedded in shares based upon the differences between the fair value of the underlying common stock at the commitment date of the transaction and the effective conversion price embedded in the shares.

(h)

Accounts Receivable

Accounts receivables are derived from products and services delivered to customers and are stated at their net realizable value. Each month, the Company reviews its receivables on a customer-by-customer basis and evaluates whether an allowance for doubtful accounts is necessary based on any known or perceived collection issues. Any balances that are eventually deemed uncollectible are written off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. As of December 31, 2025, and June 30, 2025, the Company had an allowance of doubtful accounts $981,590 and $87,620 respectively.

(i)

Inventory

Inventory is recorded at the lower of cost or net realizable value on a first-in first-out basis. As December 31, 2025, and year ended June 30, 2025, inventory is comprised of raw materials purchased from suppliers, work-in-progress, and finished goods produced or purchased for resale. The Company establishes inventory reserves for estimated obsolete or unsaleable inventory equal to the difference between the cost of inventory and the estimated realizable value based upon assumptions about future market conditions.

(j)

Property and Equipment

Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful life of each asset, as follows:


	Estimated Useful Life
Computer and office equipment	3 - 5 years
Machinery and equipment	5 years
Leasehold improvements	Shorter of lease term or useful life

Estimated useful lives are periodically assessed to determine if changes are appropriate. Maintenance and repairs are charged to expense as incurred. When assets are retired or otherwise disposed of, the cost of these assets and related accumulated depreciation or amortization are eliminated from the Consolidated Balance Sheet and any resulting gains or losses are included in the Consolidated Statement of Operations in the period of disposal.

(k)

Business Combinations and Acquisitions

The Company accounts for acquisitions in which it obtains control of one or more businesses as a business combination. The purchase price of the acquired businesses is allocated to the tangible and intangible assets acquired and liabilities assumed based on their estimated fair values at the acquisition date. The excess of the purchase price over those fair values is recognized as goodwill. During the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments, in the period in which they are determined, to the assets acquired and liabilities assumed with the corresponding offset to goodwill. If the assets acquired are not a business, the Company accounts for the transaction or other event as an asset acquisition. Under both methods, the Company recognizes the identifiable assets acquired, the liabilities assumed, and any noncontrolling interest in the acquired entity. In addition, for transactions that are business combinations, the Company evaluates the existence of goodwill, indefinite life intangible assets, or a gain from a bargain purchase.

(l)

Contingent Consideration

Certain acquisitions include contingent consideration as part of the purchase price. The fair value of the contingent consideration is estimated as of the acquisition date based on the present value of the contingent payments to be made using a weighted probability of possible payments. The unobservable inputs used in the determination of the fair value of the contingent consideration include managements assumptions about the likelihood of payment based on the established benchmarks and discount rates based on internal rate of return analysis. The fair value measurement includes inputs that are Level 3 measurement as discussed in Note 4 to our consolidated financial statements included in this quarterly report on Form 10-Q. Should actual results increase or decrease as compared to the assumption used in our analysis, the fair value of the contingent consideration obligations will increase or decrease, up to the contracted limit, as applicable. Changes in the fair value of the contingent earn-out consideration could cause a material impact and volatility in our operating results. As of December 31, 2025, and June 2025, the Company had a fair value of the contingent consideration $211,289 and $211,289, respectively.

(m)

Impairment of Long-Lived Assets

The Company reviews its long-lived assets (property and equipment and amortizable intangible assets) for impairment whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable. If the sum of the expected cash flows, undiscounted, is less than the carrying amount of the asset, an impairment loss is recognized as the amount by which the carrying amount of the asset exceeds its fair value.

Goodwill is tested annually at June 30 for impairment and upon the occurrence of certain events or substantive changes in circumstances.

The annual goodwill impairment test allows for the option to first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. An entity may choose to perform the qualitative assessment on none, some or all of its reporting units or an entity may bypass the qualitative assessment for any reporting unit and proceed directly to step one of the quantitative impairment tests. If it is determined, on the basis of qualitative factors, that the fair value of a reporting unit is, more likely than not, less than its carrying value, the quantitative impairment test is required. The quantitative impairment test calculates any goodwill impairment as the difference between the carrying amount of a reporting unit and its fair value, but not to exceed the carrying amount of goodwill. During the quarter ended December 31, 2025, the Company performed a qualitative assessment of its reporting units to evaluate whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. As a result of the qualitative impairment assessment performed, the Company did not recognize goodwill impairment.

An intangible asset is an identifiable non-monetary asset without physical substance. Such an asset is identifiable when it is separable, or when it arises from contractual or other legal rights. Separable assets can be sold, transferred, licensed, etc. Examples of intangible assets include computer software, licenses, trademarks, patents, films, and copyrights. The Company’s intangible assets are finite lived assets and are amortized on a straight-line basis over the estimated useful lives of the assets.

(n)

Revenue Recognition

The Company determines revenue recognition in accordance with Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers, and its related amendments (collectively known as “ASC 606”) through the following steps:

	-	Identification of a contract with a customer;

	-	Identification of the performance obligations in the contract;

	-	Determination of the transaction price;

	-	Allocation of the transaction price to the performance obligations in the contract; and

	-	Recognition of revenue when or as the performance obligations are satisfied.

Revenue is recognized when control of the promised goods or services is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. As a practical expedient, the Company does not adjust the transaction price for the effects of a significant financing component if, at contract inception, the period between customer payment and the transfer of goods or services is expected to be one year or less.

Sales are recognized at an amount that reflects the consideration to which the Company expects to be entitled in exchange for transferring control of goods or services to the customer. The Company recognizes revenue, net of taxes and expected returns, at the time it sells merchandise, provides services or dispenses prescription drugs to the customer. The Company estimates revenue based on expected reimbursements from third-party payors (e.g., pharmacy benefit managers, insurance companies and governmental agencies) for dispensing prescription drugs. The estimates are based on all available information including historical experience and are updated to actual reimbursement amounts.

The Company recognizes revenue when control of the prescription drugs is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to receive in exchange for those prescription drugs. The Company has established the following revenue recognition policies for the Pharmacy Services segment:

Revenues generated from prescription drugs sold by mail service dispensing pharmacies are recognized when the prescription drug is delivered to the client plan member. At the time of delivery, the Company has performed substantially all of its performance obligations under its client contracts and does not experience a significant level of returns or reshipments.

The Company’s retail drugstores recognize revenue at the time the customer takes possession of the merchandise. For pharmacy sales, each prescription claim is its own arrangement with the customer and is a performance obligation, separate and distinct from other prescription claims under other retail network arrangements. Revenues are adjusted for refunds owed to third party payers resulting from pricing guarantees and performance against defined value-based service and performance metrics. The inputs to these estimates are not subject to a high degree of subjectivity or volatility.

Boost, which provides clinical testing services and other services, satisfies its performance obligations and recognizes revenues primarily upon completion of the testing process (when results are reported) or when services have been rendered. Pala does not invoice the patients themselves for testing but relies on healthcare insurers and government payers for reimbursement for COVID-19 testing. Boost has a standardized approach to estimate the amount of consideration that we expect to be entitled to, including the impact of contractual allowances (including payer denials), and patient price concessions. We regularly assess the state of our billing operations in order to identify issues which may impact the collectability of receivables or revenue estimates. We believe that the collectability of our receivables is directly linked to the quality of our billing processes, most notably those related to obtaining the correct information in order to bill effectively for the services we provide. As such, we strive to implement “best practices” and work with our third-party billing company to reduce the number of requisitions that we receive from healthcare providers with missing or incorrect billing information. We believe that our collection and revenue estimation processes, along with our close monitoring of our billing operations, help to reduce the risk associated with material adjustments to reserve estimates. However, changes to our estimate of the impact of contractual allowances (including payer denials) and patient price concessions could have a material impact on our results of operations and financial condition in the period that the estimates are adjusted. Adjustments to our estimated contractual allowances and implicit patient price concessions are recorded in the current period as changes in estimates. Although we have limited track record, further adjustments to the allowances, based on actual receipts, may be recorded upon settlement.

DES recognizes revenue on energy savings contracts where it provides design, engineering and equipment upgrades to obtain energy savings through Environmental, Social, and Governance (“ESG”) targets. DES recognizes revenue through two performance obligations: 1) the Energy Savings Report (point in time); and 2) functional IP license (point in time with a significant financing component and royalty and variable consideration constraint). Up to and upon completion of an energy savings project, DES calculates the monthly energy savings based on prior and current energy consumption totals. Upon completion of a project, the customer pays monthly fixed payments which represents a financing component. DES recognized monthly interest income and “royalty” revenue when the constraint from the energy savings percentage is known. DES records revenue as it provides additional management, consulting, and other services as they are incurred.

DepTec and Bothof recognize revenues using a cost-based input method, by which we use actual costs incurred relative to the total estimated contract costs to determine, as a percentage, progress toward contract completion. Provisions for estimated losses on uncompleted contracts are made in the period in which such losses are determined.

The Company also earns service revenue from its other subsidiaries, including information technology and consulting services via Prakat, educational programs, and courses via DCI, management services for Genefic Wellness Group, and custom parts manufacturing for Dalrada Precision Parts. For Prakat, Genefic Wellness Group, Grand Entrances and Dalrada Precision Parts, revenues are recognized when performance obligations have been satisfied and the services are complete. This is generally at a point of time upon written completion and client acceptance of the project or product, which represents transfer of control to the customer. For DCI, revenues are recognized over the course of a semester while services are performed.

Disaggregation of Revenue

The following table presents the Company’s revenue disaggregated by revenue source:

Schedule of disaggregated revenue
	Three Months Ended						Six Months Ended
	December 31,						December 31,
	2025			2024			2025		2024
Product sales - third parties	$	311,540		$	908,633		$	1,481,589	$	4,529,891
Product sales - related party		–			(140	)		–		–
Service revenue - third parties		2,974,165			1,899,535			5,324,180		4,089,844
Service revenue - related party		(25,772	)		306,830			552,950		525,778
Total revenue	$	3,259,933		$	3,114,858		$	7,358,719	$	9,145,513

Accounts Receivable and Deferred Revenue

The following table provides information about receivables and contract liabilities from contracts with customers:


	December 31,		June 30,
	2025		2025
Accounts receivable, net	$	2,092,232	$	2,747,194
Accounts receivable, net - related parties		1,318,508		1,093,620
Long-term receivables		0		18,261
Long-term receivables - related parties		1,464,132		913,036
Deferred revenue		1,616,653		1,506,686

The Company invoices customers based upon contractual billing schedules, and accounts receivable are recorded when the right to consideration becomes unconditional. Contract liabilities represent a set-up fee prepayment received from a customer in advance of performance obligations met.

(o)

Cost of Revenue

Cost of revenue consists primarily of inventory sold for product sales and direct labor for information technology and consulting services. The following table is a breakdown of cost of revenue:

Schedule of cost of revenue
	Three Months Ended				Six Months Ended
	December 31,				December 31,
	2025		2024		2025		2024
Product sales	$	241,082	$	906,858	$	1,092,700	$	4,242,590
Service revenue		1,893,954		1,373,118		4,580,944		2,904,874
Total cost of revenue	$	2,135,036	$	2,279,976	$	5,673,644	$	7,147,464

(p)

Advertising

Advertising costs are expensed as incurred. During the three months ended December 31, 2025 and 2024, advertising expenses were approximately $46,927 and $79,264, respectively. During the six months ended December 31, 2025 and 2024, advertising expenses were approximately $117,638 and $107,309, respectively.

(q)

Stock-based Compensation

The Company records stock-based compensation in accordance with ASC 718, Compensation – Stock Compensation using the fair value method. All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. Equity instruments issued to employees and the cost of the services received as consideration are measured and recognized based on the fair value of the equity instruments issued. During the three months ended December 31, 2025 and 2024, stock-based compensation was $159,550 and $379,083, respectively. During the six months ended December 31, 2025 and 2024, stock-based compensation expense was $290,800 and $1,383,026, respectively.

(r)

Foreign Currency Translation

The functional currency of the Company is the United States dollar. The functional currency of the Likido, DepTec, and Dalrada Technology subsidiaries is the Great British Pound. The functional currency of Prakat is the Indian Rupee. The functional currency of Dalrada Technology Spain is the Euro. The financial statements of the Company’s subsidiaries were translated to United States dollars in accordance with ASC 830, Foreign Currency Translation Matters, using period-end rates of exchange for assets and liabilities, and average rates of exchange for the year for revenues and expenses. Gains and losses arising on foreign currency denominated transactions are included in condensed consolidated statements of operations.

(s)

Comprehensive Loss

ASC 220, Comprehensive Income, establishes standards for the reporting and display of comprehensive loss and its components in the condensed consolidated financial statements. During the three and six months ended December 31, 2025, and 2024, the Company’s only component of comprehensive loss was foreign currency translation adjustments.

(t)

Non-controlling Interests

Non-controlling interests are classified as a separate component of equity in the Company’s condensed consolidated balance sheets and condensed consolidated statements of changes in stockholders’ equity (deficit). Net loss attributable to non-controlling interests are reflected separately from consolidated net loss in the condensed consolidated statements of comprehensive loss and condensed consolidated statements of changes in stockholders’ equity (deficit). Any change in ownership of a subsidiary while the controlling financial interest is retained is accounted for as an equity transaction between the controlling and non-controlling interests. In addition, when a subsidiary is deconsolidated, any retained non-controlling equity investment in the former subsidiary will be initially measured at fair value and the difference between the carrying value and fair value of the retained interest will be recorded as a gain or loss.

As of December 31, 2025, and June 30, 2025, non-controlling interests pertained to the Company’s Prakat subsidiary.

(u)

Basic and Diluted Net Loss per Share

The Company computes net income (loss) per share in accordance with ASC 260, Earnings per Share. ASC 260 requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the income statement. Basic EPS is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the periods using the treasury stock method and convertible preferred stock using the if-converted method. In computing diluted EPS, the average stock price for the periods is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants.

The weighted average number of common stock equivalents related to cashless warrants are 59,846,719 and 54,114,779 for the three and six months ended December 31, 2025 and 2024, respectively, and was not included in diluted loss per share, because the effects are antidilutive.

There were no adjustments to the numerator during the three and six months ended December 31, 2025, and 2024.

(v)

Income Taxes

The Company accounts for income taxes using the asset and liability method in accordance with ASC 740, Accounting for Income Taxes. The asset and liability method provides that deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using the currently enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company records a valuation allowance to reduce deferred tax assets to the amount that is believed more likely than not to be realized. The Company had a full valuation allowance at December 31, 2025, and June 30, 2025.

(w)

Recent Accounting Pronouncements

In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2023-07, Improvements to Reportable Segment Disclosures (Topic 280). This ASU updates reportable segment disclosure requirements by requiring disclosures of significant reportable segment expenses that are regularly provided to the Chief Operating Decision Maker (“CODM”) and included within each reported measure of a segment's profit or loss. This ASU also requires disclosure of the title and position of the individual identified as the CODM and an explanation of how the CODM uses the reported measures of a segment’s profit or loss in assessing segment performance and deciding how to allocate resources. This ASU was adopted in our fiscal year 2025.

In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”). The ASU includes amendments requiring enhanced income tax disclosures, primarily related to standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. ASU 2023-09 was effective for us for the fiscal year ended January 31, 2026. This guidance was applied on a prospective basis and retrospectively.

In November 2024, the FASB issued ASU 2024-03, Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (“ASU 2024-03”) and in January 2025, the FASB issued ASU 2025-01, Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date (“ASU 2025-01”), which clarified the effective date of ASU 2024-03. ASU 2024-03 is intended to improve disclosures about a public business entity’s expenses, primarily through additional disaggregation of income statement expenses. ASU 2024-03 will be effective for the annual period beginning after December 15, 2026 and interim reporting periods within annual reporting periods beginning after December 15, 2027, with the option to early adopt at any time prior to the effective date and should be applied either prospectively to financial statements issued for reporting periods after the effective date or retrospectively to any or all prior periods presented in the financial statements. We are currently evaluating the impact of the standard on our financial statements and disclosures.

3.	Business Combinations and Asset Acquisition

Fiscal 2025 Transactions

Grand Entrances

On August 21, 2024, the Company acquired 100% of Grand Entrances through a Purchase Agreement. Grand Entrances is a California based custom door and hardware retail store. Pursuant to the terms of the transaction, the Company acquired all assets, tangible and intangible, which relate to, or are used or held for use in connection with the business in consideration of $100 in cash, assumption of all liabilities, and a 20% earnout of Earnings Before Interest, Taxes, Depreciation and Amortization (“EBITDA”) over a 3-year period.

As a result of the 20% earnout of EBITDA over a 3-year period, the Company recorded contingent consideration (see Note 2. Summary of Significant Accounting Policies) in connection with the acquisition. The following is a summary of the purchase price consideration:


Cash - Payment	$	100
Contingent consideration		211,289
Total purchase price consideration	$	211,389

The Company acquired Grand Entrances to vertically integrate custom door and hardware products into Bothof Brothers’ real estate construction pipelines and scale its profit margins.

The Grand Entrances transaction was accounted for as a business combination in accordance with ASC Topic 805, Business Combinations (“ASC 805”). The Company has determined preliminary fair values of the assets acquired and liabilities assumed. These values are subject to change as we perform additional reviews of our assumptions utilized.

The Company has made a preliminary allocation of the purchase price regarding the acquisition related to the assets acquired and liabilities assumed as of the purchase date. The following table summarizes the purchase price allocation as of August 21, 2024:

Schedule of purchase price allocation
	Preliminary Purchase Price Allocation
Cash and cash equivalents	$	24,069
Accounts receivable, net		207,335
Prepaid expenses		28,917
Inventory		182,281
Property and equipment, net		55,405
Goodwill		185,269
Accounts payable		(141,064	)
Deferred revenue		(2,186	)
Ally loan		(10,515	)
Fundation loan		(84,677	)
MCA servicing loan		(83,445	)
BA EIDL loan		(150,000	)
Purchase price consideration	$	211,389

4.	Selected Balance Sheet Elements

Inventories

Inventories consisted of the following as of December 31, 2025 and June 30, 2025:

Schedule of inventories
	December 31,		June 30,
	2025		2025
Raw materials	$	225,793	$	977,224
Work-in-progress		766,682		1,638,330
Finished goods		1,725,575		74,291
Total inventories	$	2,718,050	$	2,689,845

Property and Equipment, Net

Property and equipment, net consisted of the following as of December 31, 2025 and June 30, 2025:

Schedule of property and equipment, net
	December 31,			June 30,
	2025			2025
Machinery and equipment	$	1,617,681		$	1,645,788
Leasehold improvements		589,793			557,524
Computer and office equipment		603,853			583,350
Property and equipment, gross		2,811,327			2,786,662
Less: Accumulated depreciation		(1,727,276	)		(1,513,347	)
Property and equipment, net	$	1,084,051		$	1,273,315

Depreciation expense was $125,217 and $113,205 for the three months ended, and $213,929 and $269,269 for the six months ended December 31, 2025, and 2024, respectively, were included in selling, general and administrative expenses in the condensed consolidated statements of operations and comprehensive loss.

Intangible Assets, Net

Intangible assets, net consisted of the following as of December 31, 2025:

Schedule of intangible assets, net
													Developed
													technology,
	Curriculum						Customer						software,
	development			Licenses			relationships			Trademarks			and other			Totals

Balance: June 30, 2025	$	693,385		$	969,000		$	1,341,680		$	535,547		$	953,348		$	4,492,960
Additions		–			–			–			–			–			–
Balance: December 31, 2025		693,385			969,000			1,341,680			535,547			953,348			4,492,960

Less: Accumulated amortization
Balance: June 30, 2025		(310,908	)		(62,281	)		(410,766	)		(234,402	)		(363,777	)		(1,382,134	)
Additions		(34,669	)		(27,839	)		(67,084	)		(29,405	)		(36,639	)		(195,636	)
Balance: December 31, 2025		(345,577	)		(90,120	)		(477,850	)		(263,807	)		(400,416	)		(1,577,770	)

Net book value: December 31, 2025	$	347,808		$	878,880		$	863,830		$	271,740		$	552,932		$	2,915,190

Amortization expense of $195,802 and $248,282 for the six months ended, and $96,289 and $94,373 for the three months ended, December 31, 2025, and 2024, respectively, were included in selling, general and administrative expenses in the condensed consolidated statements of operations and comprehensive loss. The Company’s intangible assets are subject to amortization and are amortized over the straight-line methods over their estimated period of benefit.

5. Notes Receivable

Notes Receivable – Related Parties

On October 1, 2025, the Company executed a loan agreement with Bandy Ranch Development, LLC for an initial principal target amount of $120,000, with a total loan amount not to exceed $250,000. The interest rate of the loan is 6%. The proceeds of the loan are to assist the financing for the construction and development of six residential homes. The loan shall be secured by the project proceeds and related accounts receivable. As of December 31, 2025, the principal balance was $40,000 and accrued interest was $0.

6.	Notes Payable

Notes Payable - Related Parties

The following is a summary of notes payable – related parties on December 31, 2025 and June 30, 2025:


	December 31, 2025
	Outstanding		Accrued
	Principal		Interest
Related entity 2	$	1,922,031	$	256,053
Related entity 4		1,624,179		111,528
Related entity 6		1,094,101		35,437
	$	4,640,311	$	403,018

	June 30, 2025
	Outstanding		Accrued
	Principal		Interest
Related entity 2	$	866,244	$	117,920
Related entity 4		714,196		33,909
Related entity 6		120,975		18,615
	$	1,701,415	$	170,444

The following is a summary of current and long-term notes payable – related parties as of December 31, 2025 and June 30, 2025:


	December 31, 2025
	Current		Long-Term
	Portion		Portion		Total
Related entity 2	$	–	$	1,922,031	$	1,922,031
Related entity 4		–		1,624,179		1,624,179
Related entity 6		–		1,094,101		1,094,101
	$	–	$	4,640,311	$	4,640,311

	June 30, 2025
	Current		Long-Term
	Portion		Portion		Total
Related entity 2	$	–	$	866,244	$	866,244
Related entity 4		–		714,196		714,196
Related entity 6		–		120,975		120,975
	$	–	$	1,701,415	$	1,701,415

Notes Payable

Notes payable includes the following:

Schedule of note payable
	December 31,		June 30,
	2025		2025
Current portion	$	4,096,187	$	3,937,797
Long-term portion		5,028,437		4,926,416
Total	$	9,124,624	$	8,864,213

The Company’s Economic Injury Disaster Loan (“EIDL”) dated May 10, 2020, include a 3.75% interest rate for up to 30 years; the payments are deferred for the first two years (during which interest will accrue), and payments of principal and interest are made over the remaining 28 years. The EIDL loan has no penalty for prepayment. The EIDL loan attaches collateral which includes the following property that EIDL borrower owns or shall acquire or create immediately upon the acquisition or creation thereof: all tangible and intangible personal property, including, but not limited to: (a) inventory, (b) equipment, (c) instruments, including promissory notes (d) chattel paper, including tangible chattel paper and electronic chattel paper, (e) documents, (f) letter of credit rights, (g) accounts, including health-care insurance receivables and credit card receivables, (h) deposit accounts, (i) commercial tort claims, (j) general intangibles, including payment intangibles and software and (k) as-extracted collateral as such terms may from time to time be defined in the Uniform Commercial Code. The security interest the EIDL borrower grants includes all accessions, attachments, accessories, parts, supplies and replacements for the collateral, all products, proceeds and collections thereof and all records and data relating thereto. The balance of the Company’s EIDL is $150,005 as of December 31, 2025, and 2024, respectively. The EIDL loan is technically in default as a result of a change in ownership without the Small Business Administration (“SBA”) prior written consent. The Company has contacted the SBA regarding the transfer of ownership and has not yet finalized the transfer of ownership.

The Company’s COVID-19 Government Loan includes a 2.5% interest rate for up to six years; the payments are deferred for the first year (during which interest will accrue). The balance of COVID-19 Government Loan is $5,147 and $12,217 as of December 31, 2025, and 2024, respectively.

The Company has a loan totaling $54,269 and $81,359 as of December 31, 2025, and 2024, respectively. The loan is collateralized by personal property and includes twelve monthly payments in the amount of 5,137.50. The Company renewed a loan on June 26, 2023, for $176,836, which includes an interest rate equal to the Wall Street Journal Prime Rate, or 8.25% as of June 30, 2023, and a maturity date of June 26, 2024. The Company renewed the loan again on November 21, 2025, for $58,717, which includes an interest rate of 9.00%

On July 25, 2023, the Company entered into an agreement with OnPoint LTB, LLC, for a credit line and funding of up to $2,000,000. The terms of the credit line include a 24-month term loan, with interest only for 6 months, then amortizing over 18 months down to 50%, with the remaining 50% of the balance due at the end of term. Interest is fixed at 20% per annum, with an origination fee of $20,000 which is added to the loan balance. The Company borrowed the first installment of $1,200,000 at the time of closing and the remaining $800,000 was borrowed on October 4, 2023. As part of the loan origination fee, the Company issued 500,000 shares of its common stock. The transaction includes a debt discount of $189,971 which is amortized using an effective interest method over a 24-month period. The net balance of the loan is $913,981 as of as of December 31, 2025.

On January 4, 2024, the Company executed a revenue purchase agreement with NewCo Capital Group LLC for $350,000, which includes a 17% purchase percentage and a total purchased amount of $507,500 at the end of the term. The agreement includes a $10,500 underwriting fee and a $10,500 origination fee. The debt was fully paid as of June 30, 2025.

On January 22, 2024 a loan and security agreement was executed with Nautilus Parent Holding, LLC whereby the Company can borrow 80% of the estimated accounts receivable at 2% interest per month for up to a maximum draw down of $750,000. On April 18, 2024, the Company board of directors approved to increase the maximum draw down to $8,000,000. As of December 31, 2025, the total drawdown was $6,445,000. The agreement includes a $5,000 expense deposit.

On May 2, 2024, the Company executed a revenue purchase agreement with Credit Line Capital Group for $600,000, which includes a 14% purchase percentage and a total purchased amount of $786,000 at the end of the term. The agreement includes a $6,000 underwriting fee and a $6,000 origination fee. The net balance due is $18,550 as of December 31, 2025.

On May 16, 2024, the Company entered into a promissory note with 1800 Diagonal Lending, LLC for $122,475. The promissory note includes a one-time interest charge of 14%, which was applied on the issuance date, and matures on March 30, 2025. There are 10 monthly payments in the amount of $13,962 for a total payback of $139,621. The debt was fully paid as of June 30, 2025.

On May 16, 2024, the Company entered into a term loan with Agile Capital Funding, LLC for $525,000 and includes an administrative fee in the amount of $23,625. There are 32 weekly payments in the amount of $22,641 for a total payback of $724,500. The debt was fully paid as of June 30, 2025.

On June 25, 2024, the Company executed a revenue purchase agreement with Cucumber Capital LLC for $325,000, which includes a 9% purchase percentage and a total purchased amount of $487,175 at the end of the term. The agreement includes a $19,500 origination fee. The debt was fully paid as of June 30, 2025.

On July 29, 2024, the Company executed a revenue purchase agreement with Tycoon Capital Group with a total advance of $125,000 and payback of $187,375. The debt was fully paid as of June 30, 2025.

On August 23, 2024, the Company executed a revenue purchase agreement with Quick Funding with a total advance of $170,000 and payback of $254,150. The debt was fully paid as of June 30, 2025.

On September 20, 2024, the Company executed a revenue purchase agreement with QFS Capital, LLC with a total advance of up to $1,573,781 and payback of $2,359,097. The net balance due is $137,616 as of December 31, 2025.

On September 18, 2025, the Company entered into a promissory note with Vanquish Funding Group, Inc. for $140,300. The promissory note includes a one-time interest charge of 14%, which was applied on the issuance date, and matures on July 30, 2026. There is 1 monthly payment of $95,965 due on March 30, 2026 and 4 subsequent monthly payments in the amount of $15,994 for a total payback of $159,942. The balance due as of December 31, 2025 is $140,300.

On November 6, 2025, the Company entered into a revenue purchase agreement with AMF Team Inc. for $100,000, which includes a 45% purchase rate and a total purchased amount of $199,900 at the end of the term. The agreement includes $50,000 in closing costs. The net balance due is $0 as of December 31, 2025.

On November 14, 2025, the Company entered into a revenue purchase agreement with Flow Capital Funding for $150,000, which includes a 15% purchase rate and a total purchased amount of $219,000 at the end of the term. The agreement includes $12,000 in closing costs. The net balance due is $124,376 as of December 31, 2025.

On November 14, 2025, the Company entered into a revenue purchase agreement with Quick Funding Group for $150,000, which includes a 20% purchase rate and a total purchased amount of $220,500 at the end of the term. The agreement includes $12,250 in closing costs. The net balance due is $126,648 as of December 31, 2025.

On November 17, 2025, the Company entered into a promissory note with Vanquish Funding Group, Inc. for $94,300. The promissory note includes a one-time interest charge of 14%, which was applied on the issuance date, and matures on August 15, 2026. There are nine payments each in the amount of $11,945 for a total payback of $107,502. The balance due as of December 31, 2025 is $85,786.

On December 16, 2025, the Company entered into a revenue purchase agreement with Verve Funding for $150,000, which includes a 5.04% purchase rate and a total purchased amount of $225,000 at the end of the term. The agreement includes $10,227 in closing costs. The net balance due is $145,539 as of December 31, 2025.

On December 16, 2025, the Company entered into a revenue purchase agreement with Alpha Equity Fund for $130,000, which includes a 25% purchase rate and a total purchased amount of $194,870 at the end of the term. The agreement includes $13,000 in closing costs. The net balance due is $132,854 as of December 31, 2025

On December 22, 2025, the Company entered into a revenue purchase agreement with MCI Group LLC dba CC Split for $75,000, which includes a 5.55% purchase rate and a total purchased amount of $112,500 at the end of the term. The agreement includes $7,500 in closing costs. The net balance due is $69,930 as of December 31, 2025.

7.	Convertible Note Payable – Related Parties

On June 30, 2024, the Company converted $3,924,499 of related party debt principal and interest into 4,700 shares of Series I Convertible Preferred Stock (“Series I Stock”). The Series I Stock shall convert at one share of Series I Stock to 5,000 shares of common stock (equivalent to converting the related dollars into common shares at $0.167 per share). The Series I Stock does not have voting rights.

On June 25, 2025, the Company converted $11,861,578 of related party debt principal and interest into 14,205 shares (effective price of $835 per share) of Series I Convertible Preferred Stock (“Series I Stock”). The Series I Stock shall convert at one share of Series I Stock to 5,000 shares of common stock (equivalent to converting the related dollars into common shares at $0.167 per share). The Series I Stock does not have voting rights. The Company issued these shares of common stock pursuant to the exemption from registration provided by Section 3(a)(9) of the Act in that such issuance did not constitute a public offering.

8.	Related Party Transactions

Fiscal 2026 Transactions

During the six months ended December 31, 2025 and 2024, the Company received cash funding or expenses paid on behalf of the Company from related parties. The expenses paid on their behalf primarily relate to operational expenditure and payroll. In most cases, promissory notes were created on a quarterly basis totaling the amounts referenced above. The remaining amounts are included within accounts payable – related parties for which the related parties expect repayment. The above-referenced expenses relate to three corporations that the Company has classified as related parties. These corporations are all owned and/or operated by an individual who has a familial relationship with the Company’s CEO.

As of December 31, 2025 and June 30, 2025 amounts included within accounts payable and accrued liabilities – related parties for related party expenses was $8,583,606 and $5,962,476, respectively. The increase of $2,621,130 is primarily attributable to payroll related expenditures.

Fiscal 2025 Transactions

During the year ended June 30, 2025, the Company received cash funding or expenses paid on behalf of the Company from related parties totaling $16,473,716. The expenses paid on their behalf primarily relate to operational expenditure and payroll. In most cases, promissory notes were created on a quarterly basis totaling the amounts referenced above. The remaining amounts are included within accounts payable – related parties for which the related parties expect repayment. The above-referenced expenses relate to three corporations that the Company has classified as related parties. These corporations are all owned and/or operated by an individual who has a familial relationship with the Company’s CEO.

As of June 30, 2025, amounts included within accounts payable and accrued liabilities – related parties for related party expenses were $2,514,302.

During the year ended June 30, 2025, the Company’s Bothof Brothers and Grand Entrances subsidiaries recognized revenue for construction services and custom door sales totaling $1,602,577 and $77,896, respectively, from corporations owned and/or operated by a related party who has a familial relationship with the Company’s CEO.

As of December 31, 2025 and June 30, 2025 amounts included within accounts payable and accrued liabilities – related parties for related party expenses was $8,583,606 and $2,514,302, respectively.

The following is a summary of revenues recorded by the Companies to related parties with common ownership:

Schedule of related party revenues
	Three Months Ended				Six Months Ended
	December 31,				December 31,
	2025		2024		2025		2024
Bothof Brothers	$	2,626	$	306,830	$	581,348	$	525,778
	$	2,626	$	306,830	$	581,348	$	525,778

See Notes 5, 7, 9, 10, and 11 for additional related party transactions.

9.	Preferred Stock

On March 29, 2024, the Company converted $13,318,943 of related party debt principal and interest into 15,951 shares (effective price of $835 per share) of Series I Convertible Preferred Stock (“Series I Stock”). The Series I Stock shall convert at one share of Series I Stock to 5,000 shares of common stock (equivalent to converting the related dollars into common shares at $0.167 per share). The Company issued these shares of common stock pursuant to the exemption from registration provided by Section 3(a)(9) of the Act in that such issuance did not constitute a public offering.

Pursuant to the acquisition agreement dated April 6, 2022 between the Company and Silicon Services Consortium Ltd. (“SSCe”), the sellers of SSCe were to be issued 3,000,000 shares of its common stock evenly every quarter for 24 months with the initial distribution to take place on the effective date (the “Share Consideration”). If at the end of the 24-month stock distribution period, beginning on the effective date of April 7, 2022 (the “Distribution Period”), the value of common stock consideration does not equate to 4,000,000 GBP (the “Target Amount”) in value, then the Company shall issue additional stock equal to the shortfall between the value of the Share Consideration and the Target Amount (the “Valuation Shortfall”). At the end of the Distribution Period, the sellers of SSCe were to be issued an additional $4,440,000 in stock as a result of the Valuation Shortfall. The Company share price at the end of the Distribution Period was $0.20, creating an additional 22,200,000 shares of common stock due to the sellers of SSCe. Pursuant to board resolution dated May 22, 2024, Valuation Shortfall shares were issued into 4,440 shares of Series I Convertible Preferred Stock (“Series I Stock”) as opposed to common stock. The Series I Stock shall convert at one share of Series I Stock to 5,000 shares of common stock (equivalent to converting the related dollars into common shares at $0.167 per share). The Series I Stock does not have voting rights. The Company issued these shares of common stock pursuant to the exemption from registration provided by Section 4(a)(2) of the Act in that such issuance did not constitute a public offering.

On June 30, 2024, the Company converted $3,924,499 of related party debt principal and interest into 4,700 shares (effective price of $835 per share) of Series I Convertible Preferred Stock (“Series I Stock”). The Series I Stock shall convert at one share of Series I Stock to 5,000 shares of common stock (equivalent to converting the related dollars into common shares at $0.167 per share). The Series I Stock does not have voting rights. The Company issued these shares of common stock pursuant to the exemption from registration provided by Section 3(a)(9) of the Act in that such issuance did not constitute a public offering.

On October 3, 2024, the Company converted an additional 781,670 shares of its common stock related to the SSCe Valuation Shortfall shares to 156 shares of Series I Stock.

On October 14, 2024, the Company converted 4,596 shares of Series I Stock to 22,981,670 shares of its common stock.

There were various related party debt convertible notes that occurred during 2025 and 2024 (see “Note 7. Convertible Note Payable – Related Parties” for more information).

10.

Stockholders’ Equity

Common Stock Transactions – Fiscal 2025

On October 14, 2024, the Company converted 4,596 shares of Series I Stock to 22,981,670 shares of its common stock.

In February 2025, the Company approved a consulting agreement whereby the consultant shall be issued 3,000,000 shares of common stock over a three-year period beginning May 1, 2024. The consulting fees associated with the consulting agreement is $33,000 and amortized over the three-year period.

11.

Stock-Based Compensation

Schedule of warrants outstanding
						Weighted
	Common			Weighted		Average
	Stock			Average		Remaining
	Warrants			Exercise Price		Contractual Life
Outstanding - June 30, 2024		54,114,779		$	0.26	8.27
Granted		3,855,000			0.13
Exercised		–			–
Forfeited		(648,174	)		–
Outstanding - June 30, 2025		57,321,605		$	0.25	7.62
Granted		3,000,000			–
Exercised		–			–
Forfeited		(474,886	)		–
Outstanding – December 31, 2025		59,846,719		$	0.24	6.98
Exercisable – December 31, 2025		59,549,384		$	0.26	6.82

The Company recorded stock-based compensation of $144,777 and $379,083 for the three months ended December 31, 2025 and 2024, and $276,027 and $1,383,026 for the six months ended December 31, 2025 and 2024, respectively. Total unrecognized compensation cost of non-vested options was $316,354 on December 31, 2025, which will be recognized through fiscal year ending June 30, 2029.

12.

Segment Reporting

The Company operates in 5 separate divisions and is managed by a single management team whose chief operating decision maker is the Chief Executive Officer, who evaluates segment performance based on operating income (loss) for purposes of allocating resources and evaluating financial performance.

Segment information for the three months ended December 31, 2025, and 2024 is as follows:

Schedule of segment information
	Three Months Ended December 31, 2025
	Genefic			Dalrada Climate Technology			Dalrada Precision Manufacturing			Dalrada Technologies			Corporate			Consolidated
Revenues	$	1,549,570		$	1,264,184		$	137,641		$	308,538		$	–		$	3,259,933
Cost of revenues		721,025			1,111,029			83,822			215,027			4,133			2,135,036
Selling, general and administration		1,286,702			1,386,039			290,242			107,854			1,627,371			4,698,209
Research and development		–			–			–			–			–			–
Goodwill impairment		–			–			–			–			–			–
Other segment expenses		–			–			–			–			–			–
Income (loss) from operations		(458,157	)		(1,232,884	)		(236,423	)		(14,343	)		(1,631,504	)		(3,573,312	)
Other income (expenses)		(564,358	)		(102,419	)		1,716			(1,586	)		(170,123	)		(836,770	)
Income tax benefit (provision)		(7,500	)		–			–			–			(7,000	)		(14,500	)
Net income (loss)		(1,030,015	)		(1,335,303	)		(234,707	)		(15,929	)		(1,808,627	)		(4,424,582	)


	Three Months Ended December 31, 2024
	Genefic			Dalrada Climate Technology			Dalrada Precision Manufacturing			Dalrada Technologies			Corporate			Consolidated
Revenues	$	1,739,251		$	1,071,890		$	21,534		$	282,183		$	–		$	3,114,858
Cost of revenues		1,494,316			544,745			25,712			205,443			9,760			2,279,976
Selling, general and administration		2,203,883			1,106,810			428,867			199,462			1,941,741			5,880,763
Research and development		–			–			–			–			–			–
Goodwill impairment		–			–			–			–			–			–
Other segment expenses		–			–			–			–			–			–
Income (loss) from operations		(1,958,948	)		(579,665	)		(433,045	)		(122,722	)		(1,951,501	)		(5,045,881	)
Other income (expenses)		(963,494	)		(27,778	)		(60,828	)		(2,089	)		(639,569	)		(1,693,758	)
Income tax benefit (provision)		(2,524	)		–			–			–			(5,000	)		(7,524	)
Net income (loss)		(2,924,966	)		(607,443	)		(493,873	)		124,811			(2,596,070	)		(6,747,163	)


	Six Months Ended December 31, 2025
	Genefic			Dalrada Climate Technology			Dalrada Precision Manufacturing			Dalrada Technologies			Corporate			Consolidated
Revenues	$	3,508,387		$	3,012,653		$	239,509		$	598,170		$	–		$	7,358,719
Cost of revenues		2,345,117			2,728,393			187,680			403,023			9,431			5,673,644
Selling, general and administration		2,671,970			2,857,788			690,590			221,737			4,135,566			10,577,651
Research and development		–			–			–			–			–			–
Goodwill impairment		–			–			–			–			–			–
Other segment expenses		–			–			–			–			–			–
Income (loss) from operations		(1,508,700	)		(2,573,528	)		(638,761	)		(26,590	)		(4,144,997	)		(8,892,576	)
Other income (expenses)		(1,243,977	)		(123,476	)		(2,920	)		(3,754	)		(194,767	)		(1,568,894	)
Income tax benefit (provision)		(7,500	)		–			–			–			(18,680	)		(26,180	)
Net income (loss)		(2,760,177	)		(2,697,004	)		(641,681	)		(30,344	)		(4,358,444	)		(10,487,650	)


	Six Months Ended December 31, 2024
	Genefic			Dalrada Climate Technology			Dalrada Precision Manufacturing			Dalrada Technologies			Corporate			Consolidated
Revenues	$	6,203,351		$	1,971,522		$	252,609		$	717,851		$	–		$	9,145,513
Cost of revenues		5,279,591			1,168,159			241,801			440,910			17,003			7,147,464
Selling, general and administration		4,329,899			2,706,467			692,504			323,337			4,713,797			12,766,004
Research and development		–			–			–			–			–			–
Goodwill impairment		–			–			–			–			–			–
Other segment expenses		–			–			–			–			–			–
Income (loss) from operations		(3,408,483	)		(1,903,104	)		(681,696	)		(46,396	)		(4,730,800	)		(10,767,955	)
Other income (expenses)		(2,004,567	)		(19,272	)		(67,826	)		(6,136	)		(672,797	)		(2,770,598	)
Income tax benefit (provision)		(2,524	)		–			–			–			(5,000	)		(7,524	)
Net income (loss)		(5,415,574	)		(1,922,376	)		(749,522	)		(52,532	)		(5,408,597	)		(13,546,077	)

Geographic Information

The following table presents revenue by country:

Schedule of revenue by country
	Six Months Ended
	December 31,
	2025		2024
United States	$	6,279,439	$	8,108,984
Scotland		186,069		197,477
Spain		317,391		412,244
India		575,820		426,808
	$	7,358,719	$	9,145,513

The following table presents inventories by country:

Schedule of inventories by country
	December 31,		June 30,
	2025		2025
United States	$	158,073	$	205,049
Scotland		2,559,977		2,484,796
	$	2,718,050	$	2,689,845

The following table presents property and equipment, net, by country:


	December 30,		June 30,
	2025		2025
United States	$	966,584	$	1,142,344
Scotland		73,297		80,084
Spain		39,850		44,966
India		4,320		5,921
	$	1,084,051	$	1,273,315

13.

Commitments and Contingencies

Lease Commitments - Operating Leases

Right of Use Assets and Liabilities

In August 2024, the Company entered into a two-year and eight-month operating lease agreement to lease manufacturing and office space in Portland, Oregon related to the deposition technology business. The Company recognized a right-of-use asset and lease liability of $211,629 and used an effective borrowing rate of 8.0% within the calculation. Imputed interest is $9,483. The lease agreement matures in April 2027.

In October 2024, Grand Entrances assigned its lease to Bothof Brothers. The lease is ten-year and one-month operating lease for retail showroom and warehouse space in San Diego, California. The Company recognized a right-of-use asset and lease liability of $953,329 and used an effective borrowing rate of 8.0% within the calculation. Imputed interest is $263,371. The lease agreement matures in June 2030.

In July 2025, the Company amended the lease for a medical clinic in Metairie, Louisiana for a five-year period from October 1, 2025 through September 31, 2030 related to IV pharmaceutical services. The Company recognized a right-of use asset and lease liability of 443,226 and used an effective borrowing rate of 8.00% within the calculation. Imputed interest is $2,875.

The following are the expected maturities of lease liabilities for operating leases as of December 31, 2025, including the total amount of imputed interested related:

Schedule of minimum lease payments
Fiscal Year Ended June 30,
Remaining 2026	$	1,076,771
2027		1,630,369
2028		695,167
2029		373,076
2030		309,589
Thereafter		8,745
Total lease payments		4,093,708
Less: imputed interest		(483,344	)
Present value of lease liabilities	$	3,610,364

Other information related to operating leases as of December 31 and June 30, 2024, respectively, were as follows:

Schedule of lease information
	December 31, 2025		June 30, 2025
Weighted average remaining lease term - years		2.76		2.80
Weighted average discount rate		7.21%		7.14%

Legal Proceedings

In September 2023, Asset Group, Inc. (“Asset”) filed a breach of contract with Dalrada Health Products (“DHP”) in the Superior Court of San Diego. The case arises out of a Purchase Order wherein Asset agreed to pay DHP the sum of $3,240,000 for the purchase of 1,800,000 IRIS Ear Loop Face Masks during the COVID-19 pandemic. Asset filed a complaint alleging DHP did not have authority to sell the masks. However, DHP have provided their counsel with proof of authority and are preparing a Cross-Complaint for Asset’s material breach of the contract. This matter is currently set for trial January 31, 2025. On January 15, 2025 DHP filed a cross-complaint against Asset Group and Dimco Holdings for tortious interference with contractual business relations. DHP contends that Asset and Dimco owe DHP the profits it would have made ($3,240,000) had Dimco not interfered with the sale. A jury trial is now scheduled for April 2026. Discovery is currently ongoing.

In March 2024, MDIQ filed a breach of contract with Dalrada Technology Group, Inc. (“DHTI”) in Collin County Texas Superior Court. MDIQ was hired to process insurance claims for COVID-19 testing performed by Empower Genomics. MDIQ failed to perform yet filed a civil collection case against DHTI for failure to pay the invoices. DHTI is now in the process of counter suing for approximately $2,000,000 of unpaid claims that we would have benefitted from had MDIQ performed according to the contract. This case has now settled. Both the lawsuit and our counterclaims have been dismissed.

A former consultant, Simon Gray, and distribution representative, DePrey Company, acted in concert with supplier Zhongshan Mide Hardware Products Co., Ltd. (“Mide”) to misappropriate Fastenal Company purchase orders and ultimately extract Dalrada Manufacturing out of its contractual relationship. DHTI has filed a lawsuit against DePrey Company and Simon Gray in July for a breach of contract and intentional interference with contractual relationships in the California Southern District Court. No trial date has been set in this matter and the parties are in the process of conducting discovery.

In June 2024, DHTI filed a case in the California Southern District Court alleging, among other causes of action, fraud, breach of contract, unjust enrichment following DHTI purchasing Likido company from Stuart Cox and his failure to disclose pertinent financial liabilities he had incurred prior to the sale of the company to DHTI. Case was thought to be resolved at mediation, but Mr. Cox filed a motion to vacate the settlement agreement and proceed with litigation. The Court has denied Cox’s motions. However, the Court has allowed us to amend the complaint to further prove that Cox availed himself of California/US laws. An amended complaint was filed 1-29-2026.

On November 19, 2024, DHTI filed a lawsuit in the Southern Calif. District Court against William Bonar, Samantha and Ian MacKenzie, Jillian Hughes and Marion Bonar (“Defendants”) alleging numerous causes of action, including but not limited to fraud, tortious interference with contractual relations, and misappropriation of trade secrets. The Defendants were employed by or were directors of DHTI’s UK subsidiaries located in Scotland and England. No trial date has been set and DHTI is in the process of conducting discovery. The parties have now entered settlement discussions wherein Defendants have offered to return over 20,000,000 shares to DHTI.

On November 27, 2024, FFF Enterprises filed a lawsuit against Genefic, Inc. and DHTI as an alleged breach of a service agreement with a demand for $564,743.48. Genefic/DHTI has filed a motion to dismiss DHTI as a defendant because they were never a party to the agreement and filed an Answer on behalf of Genefic. The case has been settled and no further liability is owed.

On June 20, 2024, a former employee filed a complaint alleging numerous labor law violations after being laid off along with several other employees. A jury trial has been scheduled for May 8, 2026. DHTI is in the process of conducting in depth discovery in this matter. Settlement discussions are ongoing.

On March 27, 2025, Lamie RB Investments, LLC filed a suit for breach of a lease contract with Genefic, Inc. Lamie RB Investments, LLC is seeking damages in the amount equal to the term of the lease. Genefic, Inc. has issued discovery requests for Lamie to provide proof that they have mitigated their damages by trying to market and re-lease the property. Trial has been scheduled for June 5, 2026. Settlement discussions are ongoing.

On July 7, 2025, the Company filed a lawsuit against Wells Fargo for having released the Pala funds while the account was frozen for litigation. The lawsuit is a civil case filed in San Diego Superior Court. This case has settled and subsequently dismissed.

On August 11, 2025 Dalrada Precision Manufacturing Inc., a subsidiary of DHTI, filed a complaint in the San Diego Superior Court against Global Resources Sustainability Group, LLC and Richard Abernathy for fraud, conversion, breach of contract and violation of Bus. & Prof. Code 17200. We have filed a default against all parties.

On November 12, 2025 Cardinal Health filed a complaint for breach of contract in Ohio against Genefic Specialty RX alleging non-payment of invoices. An answer has been filed and counsel is currently working on a settlement.

On November 19, 2025, former counsel to Dalrada on the Kroger v. Genefic case filed a lawsuit for non-payment of attorney fees in San Diego Superior Court. An answer has been filed and the case is in the process of discussing a settlement.

14.

Subsequent Events

On January 21, 2026, Genefic Inc. (“Genefic”), a wholly-owned subsidiary of the Company, entered into a Master Performance Standby Letter of Credit and Guaranty Agreement dated December 31, 2025 (the “SBLC Agreement”) with IBS Equity Fund III, LLC, a division of IBS Investment Bank (the “Secured Party”). The SBLC Agreement provides for the issuance of various guarantees, including standby letters of credit, equity commitment letters, and other financial instruments, up to an aggregate commitment amount of $20,000,000. The SBLC Agreement supports a related Credit, Security, and Account Purchase Agreement (the “ARL Agreement”) dated the same day, under which the Secured Party (or its affiliate, IBS Private Credit Fund IV, LLC) may extend revolving credit through the purchase of accounts receivable on behalf of Genefic for the benefit of third-party beneficiaries in connection with Genefic’s business operations, up to $5,000,000. Key terms of the agreements include:

Availability Period: Commencing on December 31, 2025, and continuing until December 31, 2030, or earlier upon completion of specified payments or termination.

Guarantees: Under the SBLC Agreement, may include non-bank general guarantees, equity commitment letters, documentary letters of credit (governed by UCP 600 and UCC Article 5), and performance standby letters of credit (governed by ISP98), including a $5,000,000 standby letter of credit issued to back the obligations under the ARL Agreement.

Security and Collateral: Secured by a first-priority security interest in substantially all assets of Genefic, including real estate, inventory, equipment, receivables, and cash. Genefic must maintain a minimum required collateral value equal to 25% of the outstanding amount of all guarantees. Upon an event of default, the Secured Party may apply collateral to outstanding obligations.

Personal Guaranty: Brian Bonar, the Company’s Chairman and Chief Executive Officer, serves as guarantor under either agreement.

Fees and Expenses: Genefic is obligated to pay various fees, transaction expenses, and other costs including, but not limited to, $140,000 in cash at closing, a promissory note in the amount of $165,000 paid monthly in the amount of $7,652 over a 24 month period and a pre-funded warrant valued at $225,000 with mutual, unilateral repurchase rights granting Secured Party the right to purchase 5% of the fully diluted membership units of Genefic each due at closing.

Interest: Upon an event of default, unpaid obligations accrue interest at a default rate.

Covenants: Genefic must comply with affirmative covenants (e.g., financial reporting, compliance with laws) and negative covenants (e.g., restrictions on additional indebtedness, liens, or asset dispositions). Financial covenants include maintaining EBITDA to interest ratios and other metrics.

Events of Defaults include non-payment, failure to maintain minimum collateral value, breach of covenants, insolvency, or cross-defaults with other obligations. Upon default, the Secured Party may accelerate obligations, demand reimbursement, or liquidate collateral.

On January 20, 2026, the Company entered into a revenue purchase agreement with Fuji West LLC for $77,500, which includes a 4.5% purchase rate and a total purchased amount of $113,072 at the end of the term. The agreement includes $5,812 in closing costs.

On January 22, 2026, the Company entered into a revenue purchase agreement with Spring Funding HC LLC for $135,000, which includes an estimated 11.21% purchase rate and a total estimated purchased amount of $224,850 at the end of the term. The agreement includes $15,000 in closing costs.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis in conjunction with our financial statements, including the notes thereto, included in this Report. Some of the information contained in this Report may contain forward-looking statements within the meaning of Section 27A of the Securities Exchange Act of 1933, as amended (the “Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). This information may involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance, or achievements to be materially different from future results, performance or achievements expressed or implied by any forward-looking statements. Forward-looking statements which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by the use of the words “may,” “will,” “should,” “expect,” “anticipate,” “estimate,” “believe,” “intend” or “project” or the negative of these words or other variations on these words or comparable terminology. These forward-looking statements are based on assumptions that may be incorrect, and there can be no assurance that the projections included in these forward-looking statements will come to pass. Our actual results could differ materially from those expressed or implied by the forward-looking statements as a result of various factors. We undertake no obligation to update publicly any forward-looking statements for any reason, even if new information becomes available or other events occur in the future.

Our net loss and limited working capital raise substantial doubt about our ability to continue as a going concern. We incurred a net loss of $4,424,582 and $10,487,650 during the three and six months ended December 31, 2025, respectively. We will be required to raise substantial capital to fund our capital expenditures, working capital, and other cash requirements. We will continue to rely on related parties and seek other financing to complete our business plans. The successful outcome of future financing activities cannot be determined at this time and there are no assurances that, if achieved, we will have sufficient funds to execute our intended business plan or generate positive operational results.

In addition to our current deficit, we may incur additional losses during the foreseeable future, until we are able to successfully execute our business plan. There is no assurance that we will be able to obtain additional financing through private placements and/or public offerings necessary to support our working capital requirements. To the extent that funds generated from any private placements and/or public offerings are insufficient, we will have to raise additional working capital through other sources, such as bank loans and/or financings. No assurance can be given that additional financing will be available, or if available, will be on acceptable terms.

We are incurring increased costs as a result of being a publicly traded company. As a public company, we incur significant legal, accounting and other expenses that we did not incur as a private company. In addition, the Sarbanes-Oxley Act of 2002, as well as new rules subsequently implemented by the Securities and Exchange Commission, have required changes in corporate governance practices of public companies. These new rules and regulations have increased our legal and financial compliance costs and have made some activities more time-consuming and costly. For example, as a result of becoming a public company, we have created additional board committees and have adopted policies regarding internal controls and disclosure controls and procedures. In addition, we have incurred additional costs associated with our public company reporting requirements. As a result of the new rules, it may become more difficult for us to attract and retain qualified persons to serve on our Board of Directors or as executive officers. We cannot predict or estimate the amount of additional costs we may incur as a result of being a public company or the timing of such costs.

RESULTS OF OPERATIONS

Three Months Ended December 31, 2025 and 2024

The following table sets forth the results of our operations for the three months ended December 31, 2025 and 2024:

	Three Months Ended December 31, 2025
	Genefic			Dalrada Climate Technology			Dalrada Precision Manufacturing			Dalrada Technologies			Corporate			Consolidated
Revenues	$	1,549,570		$	1,264,184		$	137,641		$	308,538		$	–		$	3,259,933
Loss from Operations	$	(458,157	)	$	(1,232,884	)	$	(236,423	)	$	(14,343	)	$	(1,631,504	)	$	(3,573,312	)

	Three Months Ended December 31, 2024
	Genefic			Dalrada Climate Technology			Dalrada Precision Manufacturing			Dalrada Technologies			Corporate			Consolidated
Revenues	$	1,739,251		$	1,071,890		$	21,534		$	282,183		$	–		$	3,114,858
Loss from Operations	$	(1,958,948	)	$	(579,665	)	$	(433,045	)	$	(122,722	)	$	(1,951,501	)	$	(5,045,881	)

Revenues and Cost of Revenues

Revenues

Genefic:

Revenues for the three months ended December 31, 2025, was $1,549,570 compared with revenue of $1,739,251 during the three months ended December 31, 2024, a decrease of $189,681, or 10.9%. The decrease in revenues was primarily attributable to limited working capital to continue revenue growth and a shift in the sales pipelines of Genefic Specialty Pharmacy.

Dalrada Climate Technology:

Revenues for the three months ended December 31, 2025, was $1,264,184 compared with revenue of $1,071,890 during the three months ended December 31, 2024, an increase of $192,294, or 17.9%. The increase in revenue is due to a growth in residential development opportunities for Bothof Brothers Construction.

Dalrada Precision Manufacturing:

Revenues for the three months ended December 31, 2025, was $137,641 compared with revenue of $21,534 during the three months ended December 31, 2024, an increase of $116,107, or 539.2%. The increase in revenue is primarily attributable to finalizing projects by Deposition Technology.

Dalrada Technologies:

Revenues for the three months ended December 31, 2025, was $308,538 compared with revenue of $282,183 during the three months ended December 31, 2024, an increase of $26,355, or 9.3%. The increase in revenue was a result of closing on new contracts.

Costs and Expenses

Cost of Revenues

Genefic:

Cost of Revenues for the three months ended December 31, 2025, was $721,025 compared to cost of revenues of $1,494,316 during the three months ended December 31, 2024, a decrease of $773,291, or 51.7%. The decrease in cost of revenues was primarily a result of limited working capital to continue revenue growth and a shift in the sales pipelines of Genefic Specialty Pharmacy.

Dalrada Climate Technology:

Cost of Revenues for the three months ended December 31, 2025, was $1,111,029, compared to cost of revenues of $544,745 during the three months ended December 31, 2024, an increase of $566,284, or 204.0%.. The increase in revenue is due to a growth in residential development opportunities for Bothof Brothers Construction.

Dalrada Precision Manufacturing:

Cost of Revenues for the three months ended December 31, 2025, was $83,822 compared to cost of revenues of $25,712 during the three months ended December 31, 2024, an increase of $58,110, or 226.0%. The increase in cost of revenue is primarily attributable to finalizing projects by Deposition Technology.

Dalrada Technologies:

Cost of Revenues for the three months ended December 31, 2025, was $215,027 compared to cost of revenues of $205,443 during the three months ended December 31, 2024, an increase of $9,584 or 4.7%. The increase in cost of revenues was primarily a result of closing new contracts.

Operating Expenses

Genefic:

Operating expenses for the three months ended December 31, 2025, was $1,286,702 compared to operating expenses of $2,206,407 during the three months ended December 31, 2024, a decrease of $919,705 or 41.6%. The decrease in operating expenses was the result of an increase an overall decrease in operating activity and sales within the segment.

Dalrada Climate Technology:

Operating expenses for the three months ended December 31, 2025, was $1,386,039 compared to operating expenses of $1,106,810 during the three months ended December 31, 2024, an increase of $279,229, or 25.22%. The increase in operating expenses was a result of an increase of activity in Bothof Brothers Construction and Dalrada Technology Spain.

Dalrada Precision Manufacturing:

Operating expenses for the three months ended December 31, 2025 was $290,242 compared to operating expenses of $428,867 during the three months ended December 31, 2024, a decrease of $138,625 or 32.3%. The decrease in operating expenses was a result of a decrease in activity in all Dalrada Precision Manufacturing subsidiaries.

Dalrada Technologies:

Operating expenses for the three months ended December 31, 2025 was $107,854 compared to operating expenses of $199,462 during the three months ended December 31, 2024, a decrease of $91,608, or 45.9%. The decrease in operating expenses was primarily attributable to a decrease in overall sales volumes in Prakat.

Corporate:

Operating expenses for the three months ended December 31, 2025 was $1,627,371 compared to operating expenses of $2,012,551 during the three months ended December 31, 2024, a decrease of $385,180, or 19.1%. During the three months ended December 31, 2025 and 2024, the Company recorded stock compensation expense of $144,777 and $379,083, respectively, to consultants, employees, executives, and the Board of Directors, which is included in operating expenses.

Other Income (Expense)

Other income (expense) consists of penalties and interest within interest expense on the consolidated statements of operations. Interest expense was $844,780 and $1,033,800 for the three months ended December 31, 2025 and 2024, respectively.

Net Income (Loss)

Net loss for the three months ended December 31, 2025 was $4,424,582 compared to net loss of $6,747,163 for the three months ended December 31, 2024.

Six Months Ended December 31, 2025 and 2024

The following table sets forth the results of our operations for the six months ended December 31, 2025 and 2024:

	Six Months Ended December 31, 2025
	Genefic			Dalrada Climate Technology			Dalrada Precision Manufacturing			Dalrada Technologies			Corporate			Consolidated
Revenues	$	3,508,387		$	3,012,653		$	239,509		$	598,170		$	–		$	7,358,719
Income (Loss) from Operations	$	(1,508,700	)	$	(2,573,528	)	$	(638,761	)	$	(26,590	)	$	(4,144,997	)	$	(8,892,576	)

	Six Months Ended December 31, 2024
	Genefic			Dalrada Climate Technology			Dalrada Precision Manufacturing			Dalrada Technologies			Corporate			Consolidated
Revenues	$	6,203,531		$	1,971,522		$	252,609		$	717,851		$	–		$	9,145,513
Income (Loss) from Operations	$	(3,408,483	)	$	(1,903,104	)	$	(681,696	)	$	(46,396	)	$	(4,730,800	)	$	(10,767,955	)

Revenues and Cost of Revenues

Revenues

Genefic:

Revenues for the six months ended December 31, 2025, was $3,508,387 compared with revenue of $6,203,531 during the six months ended December 31, 2024, an decrease of 43.4%. The decrease in revenues was primarily attributable to limited working capital to continue revenue growth and a shift in the sales pipelines of Genefic Specialty Pharmacy.

Dalrada Climate Technology:

Revenues for the six months ended December 31, 2025, was $3,012,653 compared with revenue of $1,971,522 during the six months ended December 31, 2024, an increase of $1,041,131, or 52.8%. The increase in revenue is due to a growth in residential development opportunities for Bothof Brothers Construction.

Dalrada Precision Manufacturing:

Revenues for the six months ended December 31, 2025, was $239,509 compared with revenue of $252,609 during the six months ended December 31, 2024, a decrease of $13,100, or 5.2%. The decrease in revenue is due to Deposition Technology finalizing a number of projects during prior periods and reduced sales in the Precision Parts subsidiary.

Dalrada Technologies:

Revenues for the six months ended December 31, 2025, was $598,170 compared with revenue of $717,851 during the six months ended December 31, 2024, an decrease of $119,681, or 16.7%.

Costs and Expenses

Cost of Revenues

Genefic:

Cost of Revenues for the six months ended December 31, 2025, was $2,345,117 compared to cost of revenues of $5,279,591 during the six months ended December 31, 2024, a decrease of $2,934,474, or 55.6%. The decrease in cost of revenue was primarily attributable to limited working capital to continue revenue growth and a shift in the sales pipelines of Genefic Specialty Pharmacy.

Dalrada Climate Technology:

Cost of Revenues for the six months ended December 31, 2025, was $2,728,393, compared to cost of revenues of $1,168,159 during the six months ended December 31, 2024, an increase of $1,560,234, or 133.5%. The increase in cost of revenue is due to a growth in residential development opportunities for Bothof Brothers Construction.

Dalrada Precision Manufacturing:

Cost of Revenues for the six months ended December 31, 2025, was $187,680 compared to cost of revenues of $241,801 during the six months ended December 31, 2024, a decrease of $54,121, or 22.4%. The decrease in cost of revenue is due to Deposition Technology finalizing a number of projects during prior periods and reduced sales in the Precision Parts subsidiary.

Dalrada Technologies:

Cost of Revenues for the six months ended December 31, 2025, was $403,023 compared to cost of revenues of $440,910 during the six months ended December 31, 2024, a decrease of $37,887 or 8.6%.

Operating Expenses

Genefic:

Operating expenses for the six months ended December 31, 2025, was $2,671,970 compared to operating expenses of $4,332,423 during the six months ended December 31, 2024, a decrease of $1,660,453, or 38.3%. The decrease in operating expenses was the result of an increase an overall decrease in operating activity and sales within the segment.

Dalrada Climate Technology:

Operating expenses for the six months ended December 31, 2025, was $2,857,788 compared to operating expenses of $2,706,467 during the six months ended December 31, 2024, an increase of $151,321, or 5.0%. The increase in operating expenses was a result of an increase of activity in Bothof Brothers Construction and Dalrada Technology Spain.

Dalrada Precision Manufacturing:

Operating expenses for the six months ended December 31, 2025 was $690,589 compared to operating expenses of $692,504 during the six months ended December 31, 2024, a decrease of $1,915, or 0.03%. The decrease in operating expenses was a result of overall activity within the segment.

Dalrada Technologies:

Operating expenses for the six months ended December 31, 2025 was $221,737 compared to operating expenses of $323,337 during the six months ended December 31, 2024, a decrease of $101,600, or 31.4%.

Corporate:

Operating expenses for the six months ended December 31, 2025 was $4,135,566 compared to operating expenses of $4,713,797 during the six months ended December 31, 2024, a decrease of $435,922, or 9.2%. During the six months ended December 31, 2025 and 2024, the Company recorded stock compensation expense of $276,027 and $1,383,026, respectively, to consultants, employees, executives, and the Board of Directors, which is included in operating expenses.

Other Income (Expense)

Other income (expense) consists of penalties and interest within interest expense on the consolidated statements of operations. Interest expense was $1,578,118 and $2,099,614 for the six months ended December 31, 2025 and 2024, respectively.

Net Income (Loss)

Net loss for the six months ended December 31, 2025 was $10,487,650 compared to net loss of $13,546,077 for the six months ended December 31, 2024.

Liquidity and Capital Resources

The Company continues to incur significant losses and raises substantial doubt regarding the Company’s ability to continue as a going concern. We anticipate needing additional liquidity during the next twelve months to fund operations, expand our subsidiaries, expand the growth of the pharmacies, continue the commercialization of our DCT heat pump units and expanding Bothof Brothers Construction’s development footprint. Management is planning to support operations by raising capital, and by accelerating sales & marketing efforts of high-margin DCT heat pump units, precision parts, DepTec’s deposition systems and COVID-19 testing. The continuation of the Company as a going concern is dependent upon the continued financial support from its management, its ability to obtain the necessary debt or equity financing and generate profitable operations from the Company’s planned future operations. We will also continue to rely on equity sales of our common shares in order to continue to fund our business operations. Issuances of additional shares will result in dilution to existing stockholders. There is no assurance that we will achieve any additional sales of the equity securities or arrange for debt or other financing to fund planned acquisitions and activities and there are no plans to induce conversion of existing debt. There are no assurances that our plans will be successful. These financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Our primary sources of liquidity are cash from operations and cash on hand from related party loans. Our primary requirements for liquidity are to fund our working capital needs, debt service, operating lease obligations, capital expenditures and general corporate needs.

As of December 31, 2025, we maintained a cash and cash equivalents balance of $399,381 (Restricted cash CD $329,307 which will be released when the Pala project is complete with Bothof Construction which is estimated to be March 2026) with a working capital deficit of $15,341,014.

Working Capital

As of December 31, 2025, the Company had current assets of $7,169,941 and current liabilities $22,510,955 compared with current assets of $7,741,021 and current liabilities $15,742,840 on June 30, 2025. The decrease in the working capital was primarily a result of increased accounts payable to fund payroll and pay outstanding vendors as well as an increase in related party notes.

Cash Flows

	Six Months Ended
	December 31,
	2025			2024
Net cash used by operating activities	$	(3,261,788	)	$	(4,433,602	)
Net cash used in investing activities		–			(457,285	)
Net cash provided by financing activities		2,996,383			4,479,062
Net change in cash during the period, before effects of foreign currency	$	(265,405	)	$	(411,825	)

Cash flow from Operating Activities

During the six months ended December 31, 2025, the Company used $3,261,788 of cash for operating activities compared to used $4,433,602 during the six months ended December 31, 2024. The primary decrease in the use of cash for operating activities was a result of the increase in accounts payable to related parties.

Cash flow from Investing Activities

During the six months ended December 31, 2025, the Company used no cash for investing activities compared to $457,285 used during the six months ended December 31, 2024.

Cash flow from Financing Activities

During the six months ended December 31, 2025, the Company received $2,996,383 in net cash for financing activities compared to receiving $4,479,062 during the six months ended December 31, 2024. The decrease was primarily due to a reduction in proceeds from related party notes payable.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources, and related party transactions.

Critical Accounting Policies

Our financial statements and accompanying notes have been prepared in accordance with United States generally accepted accounting principles applied on a consistent basis. The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods.

We regularly evaluate the accounting policies and estimates that we use to prepare our financial statements. A complete summary of these policies is included in note (1) of the notes to our financial statements. In general, management’s estimates are based on historical experience, on information from third party professionals, and on various other assumptions that are believed to be reasonable under the facts and circumstances. Actual results could differ from those estimates made by management.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes for the reporting period. Significant areas requiring the use of management estimates relate to the valuation of its mineral leases and claims and our ability to obtain final government permission to complete the project. As of December 31, 2025 there have been no material changes to our critical accounting policies and estimates from those previously disclosed in our Annual Report on Form 10-K for the year ended June 30, 2024.

Stock-Based Compensation

The Company records stock-based compensation in accordance with ASC 718, Compensation – Stock Compensation, using the fair value method. All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. Equity instruments issued to employees and the cost of the services received as consideration are measured and recognized based on the fair value of the equity instruments issued.

Recently Issued Accounting Pronouncements

We have reviewed all recently issued, but not yet effective, accounting pronouncements and we do not believe any of these pronouncements will have a material impact on the Company.

Contractual Obligations

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

Not applicable to smaller reporting companies.

Item 4. Controls and Procedures.

(a) Evaluation of disclosure controls and procedures.

Our Chief Executive Officer and Principal Financial Officer, after evaluating the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) as of the end of the period covered by this Quarterly Report on Form 10-Q, concluded that our disclosure controls and procedures were ineffective as of that date primarily due to a material weakness in internal control over financial reporting described below.

(b) Changes in internal control over financial reporting. Material Weakness in Internal Control Over Financial Reporting Management has identified a material weakness in the Company’s internal control over financial reporting as of December 31, 2025. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis.

The identified material weakness primarily relates to preparing adequate and complete schedules across the various consolidated entities including roll forwards, revenue recognition, and allowance estimates. This deficiency could result in a reasonable possibility of material misstatements in the financial statements that would not have been prevented or detected.

Remediation Steps Being Taken

Management has taken and continues to take the following actions to remediate the material weakness:

	·	Implemented enhanced review and approval controls, including multi-level reviews for all significant transactions, journal entries, and account reconciliations, supported by detailed checklists and documentation requirements.

	·	Engaged external consultants and specialists to assist in the design, documentation, and testing of improved internal control procedures, including the adoption of new accounting software with automated controls.

Management believes these measures address the root causes of the material weakness. The Company expects the remediation to be substantially complete and fully tested by the end of the third quarter of fiscal 2026 (March 31, 2026) , at which time management anticipates concluding that the material weakness has been remediated.

However, the successful remediation of a material weakness requires sustained execution and validation through testing. There can be no assurance that the material weakness will be fully remediated on the anticipated timeline, or that additional material weaknesses will not be identified in the future. Until remediated, the Company will continue to perform additional manual procedures and reviews to mitigate the risk of misstatement.

There were no other changes in our internal control over financial reporting during the fiscal quarter ended December 31, 2025, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting aside from the ongoing remediation efforts described above.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings.

In March 2024, MDIQ filed a breach of contract with Dalrada Technology Group Inc (“DHTI”) in Collin County Texas Superior Court. MDIQ was hired to process insurance claims for COVID-19 testing performed by Empower Genomics. MDIQ failed to perform yet filed a civil collection case against DHTI for failure to pay the invoices. DHTI is now in the process of counter suing for approximately $2,000,000 of unpaid claims that we would have benefitted from had MDIQ performed according to the contract. This case has now settled. Both the lawsuit and our counterclaims have been dismissed.

A former consultant, Simon Gray, and distribution representative, DePrey Company, acted in concert with supplier Zhongshan Mide Hardware Products Co., Ltd. (“Mide”) to misappropriate Fastenal Company purhcase orders and ultimately extract Dalrada Manufacturing out of its contractual relationship. DHTI has filed a lawsuit against DePrey Company and Simon Gray in July for a breach of contract and intentional interference with contractual relationships in the California Southern District Court. No trial date has been set in this matter and the parties are in the process of conducting discovery.

On November 19, 2024, DHTI filed a lawsuit in the Southern Calif. District Court against William Bonar, Samantha and Ian MacKenzie, Jillian Hughes and Marion Bonar (“Defendants”) alleging numerous causes of action, including but not limited to fraud, tortious interference with contractual relations, and misappropriation of trade secrets. The Defendants were employed by or were directors of DHTI’s UK subsidiaries located in Scotland and England. No trial date has been set and DFCO is in the process of conducting discovery. The parties have now entered settlement discussions wherein Defendants have offered to return over 20,000,000 shares to DHTI.

On June 20, 2024, a former employee filed a complaint alleging numerous labor law violations after being laid off along with several other employees. A jury trial has been scheduled for May 8, 2026. DFCO is in the process of conducting in depth discovery in this matter. Settlement discussions are ongoing.

Item 1A. Risk Factors.

Not applicable to smaller reporting entities

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds Securities.

None.

Item 3. Defaults Upon Senior Securities.

None noted.

Item 4. Mine Safety Disclosures.

Not applicable to our Company.

Item 5. Other Information.

During the quarter ended December 31, 2025, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

Item 6. Exhibits.

Exhibit Number		Exhibit Description
31.1		Certification of the Chief Executive Officer Pursuant to Rule 13a-14 or 15d-14 of the Exchange Act pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2		Certification of the Chief Financial Officer Pursuant to Rule 13a-14 or 15d-14 of the Exchange Act pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1		Certification of the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS*		Inline XBRL Instance Document
101.SCH*		Inline XBRL Schema Document
101.CAL*		Inline XBRL Calculation Linkbase Document
101.DEF*		Inline XBRL Definition Linkbase Document
101.LAB*		Inline XBRL Label Linkbase Document
101.PRE*		Inline XBRL Presentation Linkbase Document
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Exchange Act, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.

	Dalrada Technology Group, Inc.

	By: /s/ Brian Bonar
Date: February 20, 2026	Brian Bonar
	Chief Executive Officer (Principal Executive, Accounting and Financial Officer)

Pursuant to the requirements of the Exchange Act this Report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Signature	Title	Date

/s/ Brian Bonar	Chief Executive Officer	February 20, 2026
Brian Bonar	and Director

Dalrada Technology Group, Inc. 10-Q